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Objective: Osteoarthritis (OA) is a chronic and slowly progressive disease for which biomarkers may be
able to provide a more rapid indication of therapeutic responses to therapy than is currently available;
this could accelerate and facilitate OA drug discovery and development programs. The goal of this
document is to provide a summary and guide to the application of in vitro (biochemical and other
soluble) biomarkers in the development of drugs for OA and to outline and stimulate a research agenda
that will further this goal.
Methods: The Biomarkers Working Group representing experts in the ﬁeld of OA biomarker research from
both academia and industry developed this consensus document between 2007 and 2009 at the behest
of the Osteoarthritis Research Society International Federal Drug Administration initiative (OARSI FDA
initiative).
Results: This document summarizes deﬁnitions and classiﬁcation systems for biomarkers, the current
outcome measures used in OA clinical trials, applications and potential utility of biomarkers for devel-
opment of OA therapeutics, the current state of qualiﬁcation of OA-related biomarkers, pathways for
biomarker qualiﬁcation, critical needs to advance the use of biomarkers for drug development, recom-
mendations regarding practices and clinical trials, and a research agenda to advance the science of
OA-related biomarkers.: Virginia Byers Kraus, Box 3416, Duke University Medical Center, Durham, NC 27710, USA. Tel: 1-919-681-6652;
s Research Society International. Published by Elsevier Ltd. All rights reserved.
V.B. Kraus et al. / Osteoarthritis and Cartilage 19 (2011) 515e542516Fig. 1. Continuum of OA stages as paradigms for strConclusions: Although many OA-related biomarkers are currently available they exist in various states of
qualiﬁcation and validation. The biomarkers that are likely to have the earliest beneﬁcial impact on
clinical trials fall into two general categories, those that will allow targeting of subjects most likely to
either respond and/or progress (prognostic value) within a reasonable and manageable time frame for
a clinical study (for instance within 1e2 years for an OA trial), and those that provide early feedback for
preclinical decision-making and for trial organizers that a drug is having the desired biochemical effect.
As in vitro biomarkers are increasingly investigated in the context of speciﬁc drug treatments, advances
in the ﬁeld can be expected that will lead to rapid expansion of the list of available biomarkers with
increasing understanding of the molecular processes that they represent.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
It is said that a disease starts when detected by the best marker
available to deﬁne it. To date, this usually requires the presence of
a clinical symptom, which often occurs well into the progression of
an illness or disease. However, there is signiﬁcant evidence that
there are often early, pre-symptomatic biomarkers of illness and
disease, which if detected, may allow for earlier treatment. Therein
lies the power and importance of applying biomarkers to osteoar-
thritis (OA), a disease often characterized by a prolonged asymp-
tomatic molecular phase, a pre-radiographic phase, and
a recalcitrant later radiographic phase with evident structural joint
changes, frequent pain, and loss of function (Fig. 1). Biomarkers
have the potential to provide an early warning of the initiation of
matrix breakdown that could prompt earlier treatment to prevent
the cartilage and bone destruction that leads to disability. Thus,
there currently exists a great need and opportunity for biomarkers
to provide a method for earlier diagnosis of OA, and to inform the
prognosis, monitoring and therapeutic strategies for OA. Wagner
has predicted that the next few years will see a rapid increase in the
number of drugs approved with biomarker data in their labels, and
older drugs that will have biomarker data added to their labels1. OA
may be chief among them due to the current lack of a gold standard
that comprehensively captures the disease in all of its manifesta-
tions. In addition, OA is a chronic and slowly progressive disease for
which biomarkersmay be able to provide amore rapid indication of
therapeutic response to disease structure modiﬁers than is avail-
able through currently established means; this could streamline
and optimize the discovery and development programs of new
therapeutic agents. The mandate of the Osteoarthritis Research
Society International Federal Drug Administration (OARSI FDA)
Biomarkers Working Group was 2-fold. First to create a critical
appraisal of fundamentals of the science related to biomarkers of
OA, particularly as they relate to the development of drugs intended
for the treatment of OA. Second, to address speciﬁc queries posed
by the FDA related to OA biomarkers, namely: What biomarkers
now exist? What is their utility? What evidence is available to
support surrogacy for clinical outcomes? What is the face validity?
What is the practicality? What is the research agenda required to
inform each of the above questions? Thus this document is inten-
ded to address this 2-fold purpose in the hopes of helping to
advance the development of drugs for OA.ucture modifying OA trials.Scope of the document
A previous broad ranging biomarker white paper was commis-
sioned and prepared for the launch of the National Institutes of
Health Osteoarthritis Public/Private Research Initiative and was
published on line in 2000 (and now found at the OARSI website
http://www.oarsi.org/index2.cfm?section¼OARSI_Initiatives&
content¼Biomarkers) The present document has a much more
speciﬁc focus. It also covers the great increase in biomarker
research activity in the present decade and utilizes deﬁnitions and
nomenclature that are harmonized with and expand upon those
proposed to date in FDA draft guidance documents. This current
paper covers biochemical/molecular and genomic (RNA-gene
expression, DNA-genetic polymorphisms) biomarkers of OA but
excludes imaging biomarkers and clinical risk factors such as
obesity, malalignment, and gender because other working groups
are covering these topics in companion documents. We include
a brief summary of issues related to the current methods of OA
diagnosis, treatment and response criteria for therapeutic trials,
and the challenges posed by the current ‘gold standard’ radio-
graphic trial criteria, in order to provide a framework in which to
conceptualize the role to be played by biomarkers in the develop-
ment of drugs for OA. The concept of OA as a continuum includes
early stages that may be amenable to treatment if appropriate
biomarkers are deﬁned, which in turn could complement current
treatment paradigms for established radiographic OA; prevention
versus treatment of established disease has traditionally been
referred to as primary and secondary prevention, respectively.
Potential uses and challenges for each type of biomarker based
on the BIPEDS classiﬁcation scheme (described below) in the drug
development process are discussed. Summary tables illustrating
study power for treatment effects based on varying effect sizes are
provided utilizing a theoretical biomarker as well as known soluble
biochemical OA biomarkers, and their current level of qualiﬁcation
based on published clinical trials.
A summary of the pathways required for biomarker qualiﬁcation
is included that lists the regulatory agencies involved with
biomarker development, as well as recommendations for
biomarker endpoints in trials. Clinical and scientiﬁc issues are also
raised that would beneﬁt from more research. Appendices are
provided containing recommendations for sample collection, pro-
cessing and storage, as well as a glossary of biomarker terms.Deﬁnition of biomarkers
A biomarker is a characteristic that is objectively measured and
evaluated as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic interven-
tion2. This is in contrast to a clinical endpoint that is a marker or
variable that measures how a patient feels, functions or survives. A
biomarker becomes a surrogate endpoint when it is appropriately
qualiﬁed to substitute for a clinical endpoint. The technical
V.B. Kraus et al. / Osteoarthritis and Cartilage 19 (2011) 515e542 517revolution in molecular biology has led to the expansion of the
notion of what constitutes a potential biomarker to include, not
only proteins and protein fragments, but also metabolites, carbo-
hydrate biomarkers, genomic biomarkers (RNA and DNA)3, cellular
biomarkers (could be captured for instance as the cell pellet from
body ﬂuids), and imaging biomarkers. Based on their characteris-
tics, we can divide biomarkers into two major groups: the so-called
soluble or “wet biomarkers”, usually measured in a selected body
ﬂuid such as blood, serum, plasma, urine, or synovial ﬂuid (SF) and
usually representing modulation of an endogenous substance in
these ﬂuids; and the so-called “dry biomarkers” usually consisting
of visual analog scales (VASs), questionnaires, performed tasks, or
imaging. These two types of biomarkers can also be referred to as in
vitro biomarkers (derived from in vitro diagnostics) vs in vivo
biomarkers respectively. Although many of the concepts presented
here are applicable to all of these types of biomarkers, imaging
biomarkers are dealt with more speciﬁcally in a companion docu-
ment so we focus herein on the non-imaging, in vitro, soluble
biomarkers.
Processes of biomarker qualiﬁcation and validation
Qualiﬁcation is a process applied to a particular biomarker to
support its use as a surrogate endpoint in drug discovery, devel-
opment or post-approval and, where appropriate, in regulatory
decision-making2. In contrast, validation of a biomarker is much
broader and can relate to veriﬁcation of analytical performance
characteristics (such as precision, accuracy, stability, etc) as well as
clinical correlation of a biomarker with a biological process or
clinical outcome. Current practice however is to supplant the term
validation with qualiﬁcation when the focus is on the portent
(meaning) as opposed to the performance (analytical aspects) of
the biomarker. A major difference between validation and qualiﬁ-
cation resides in the fact that the latter only has meaning in
a context. For example, qualiﬁcation of a biomarker may take into
consideration the particular level of progression of the disease and
its severity, thereby leading to the qualiﬁcation for some states of
the disease, but not for others. A systematic process has been in
development for accurate and comprehensive qualiﬁcation of
biomarkers for use in drug development4. To date, draft guidelines
exist on qualiﬁcation of genomic biomarkers2, produced by the
International Conference on Harmonisation (ICH), whose goal has
been to create a harmonized structure for qualifying the
biomarkers that will lead to consistent applications and discussions
among regulatory authorities and sponsors. Qualiﬁcation
endpoints in OA could include structural outcomes [identiﬁed with
magnetic resonance imaging (MRI), or X-ray etc], and/or clinical
outcomes (pain, function etc); biochemical and/or genomic
biomarkers are linked to modiﬁcations in these outcomes through
the process of biomarker qualiﬁcation.
Classiﬁcation systems for biomarkers
BIPEDS
In this document we refer to and use two main classiﬁcation
systems for biomarkers with modiﬁcations as described here. The
ﬁrst, a system called BIPED, classiﬁes the major types of
biomarkers5 into ﬁve categories corresponding to Burden of
Disease, Investigational, Prognostic, Efﬁcacy of Intervention, and
Diagnostic biomarkers. We have added a Safety category to the
BIPED system, and hereafter, throughout this document, refer to the
BIPEDS classiﬁcation system. This change facilitates the goal of this
document to provide a guide to the comprehensive application of
biomarkers to the study and treatment of OA. Biomarkers of safety
can be considered biomarkers able to reﬂect tissue and/or organtoxicity of an agent or intervention and are analogous to
biomarkers of toxicity in the process of evaluation and validation by
the Critical Path Initiative for diverse organ systems (see home page
http://www.fda.gov/ScienceResearch/SpecialTopics/
CriticalPathInitiative/default.htm).
Qualiﬁcation levels for biomarkers
The second useful classiﬁcation system referred to here divides
biomarkers into four categories according to their current level of
qualiﬁcation described further in Pathways for Biomarker Qualiﬁca-
tion-Levels of qualiﬁcationof biomarkers fordrugdevelopmentuse 1:
Exploration level biomarkers are research and development
tools accompanied by in vitro and/or preclinical evidence for which
there is no consistent information linking the biomarker to clinical
outcomes in humans (these are used for hypothesis generation);
Demonstration level biomarkers are associated with clinical
outcomes but have not been reproducibly demonstrated in clinical
studies (this category corresponds to “probable valid biomarkers”
in nomenclature suggested in draft guidance from the FDA6 and are
useful for decision-making by providing evidence to support the
primary clinical evidence);
Characterization level biomarkers are reproducibly linked to
clinical outcomes in more than one prospective clinical study in
humans (this category corresponds to “known valid biomarkers” in
nomenclature suggested in guidance by the FDA6 and are useful for
decision-making, dose ﬁnding, and secondary and tertiary claims);
and
Surrogacy level biomarkers can substitute for a clinical endpoint
(this category corresponds to “surrogate end point” and requires
agreement with regulatory authorities as an FDA registrable
endpoint).
Summary
As noted in a recent FDA guidance document7, the use of
biomarkers in drug discovery, development and post-approval has
the potential to facilitate development of safer and more effective
medicines; in fact, one of the main objectives of a biomarker for
drug development is to allow the construction of the dose-expo-
sureeresponse curve in patients for both the therapeutic and
toxicity effects. This will facilitate dose selection in order to reach
the best beneﬁt-risk ratio of an approved medicine. In the OA ﬁeld,
the potential also exists for biomarkers to enhance the probability
of obtaining early indications of success during clinical drug
development for OA. The selection of a new biomarker test depends
critically upon the ability of the test to link themechanism of action
of a new agent with a therapeutic response. The therapeutic
response usually addresses an unmet medical need, and in the case
of OA, there are currently no qualiﬁed biomarkers that can be
considered as surrogate clinical endpoints. Thus it is a two-edged
sword: the ultimate degree of biomarker uptake and use is inti-
mately tied to the ability to act on the biomarker information
provided, which in turn is dependent on the ability of biomarkers to
enhance the success of clinical trials to achieve the actionable result
needed for biomarkers to be adopted for clinical use.
It isworth noting here that the ﬁeld of drug development for OA is
currently analogous to osteoporosis 30 years ago8, namely a disease
in search of a robust gold standard outcome measure to inform
clinical trials. The 1979 FDA Osteoporosis Guidelines acknowledged
that evaluating the clinical effectiveness of osteoporosis drugs posed
special challenges because of the “difﬁculties in assessing the state of
skeletal bone quantitatively in vivo, the relatively small changes that
are usually encountered and the duration of studies necessary to
show signiﬁcant effects”8,9. By 1984, the FDAOsteoporosis Guidelines
upgraded dual-energy photon absorptiometry from investigational
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the spine and this was critical to the subsequent approach to the
development and regulation of osteoporosis drugs8,9. OA is at
a similar crossroads to which biomarkers may contribute substan-
tively at this time. Given the urgent need for OA therapies, it is hoped
that the concepts advanced in this document will facilitate and
stimulate the inclusion of biomarkers as secondary endpoints in all
future OA trials, and lay the groundwork for the evolution to the use
of biomarkers, in some cases, as primary endpoints.
OA diagnosis, treatment and trials
Diagnosis
The American College of Rheumatology (ACR) has developed
a set of clinical and radiological criteria for the diagnosis of hip,
knee and hand OA10e12. The ACR diagnostic criteria are based on the
association of many clinical, or clinical and radiological criteria, and
are commonly used for patient inclusion in clinical trials. These ACR
criteria are very speciﬁc and thus are useful for differentiating
patients with OA from those with inﬂammatory joint diseases.
Their sensitivity is less impressive, illustrating their limited ability
to discriminate patients with early OA from healthy controls. The
most commonly used radiographic grading system is that of
Kellgren and Lawrence (KL)13, based on the presence of osteo-
phytes, joint space narrowing (JSN), subchondral bone sclerosis and
cyst formation. This scoring system divides OA into ﬁve grades
(0e4) mainly based on the presence and number of osteophytes.
A score of 2 or more has traditionally been considered to be
a deﬁnitive radiographic diagnosis of OA and has been widely used
in clinical trials as an inclusion criterion. However, evidence
suggests that KL grade 1 is bona ﬁde OA and distinct from KL grade
0 based on subsequent risk of progression14. Based on the concept
of the disease continuum that includes a molecular stage and a pre-
radiographic stage of OA as presented in Fig. 1 and supported by the
literature15,16, even with inclusion of KL grade 1 as bona ﬁde OA,
radiographic criteriawill identify only late-stage OA. Because the KL
scoring system relies predominantly on osteophytes to determine
OA severity, the atrophic form of OA, which consists mainly of JSN,
is underestimated. The KL grading system is also known for its poor
correspondence of radiographic severity with hip or knee pain.
MRI, ultrasound or biochemical markers are not yet included in any
set of diagnostic criteria for OA.
Treatment
A cure for OA remains elusive and the management of OA is
largely palliative, focusing on the alleviation of symptoms. Current
recommendations by the European League Against Rheumatism
(EULAR), the ACR, and the OARSI for the management of OA include
a combination of non-pharmacological interventions and phar-
macological treatments. One of the main obstructions to the efﬁ-
cient development of new structure modifying therapies for OA is
the low sensitivity of change in plain radiographic endpoints that
necessitates long-term trials involving a large number of patients to
show a signiﬁcant difference between placebo and active-drug
treated groups. Biomarkers are promising sensitive tools, but they
have to demonstrate speciﬁcity for OA pathology and ideally,
provide earlier information than JSN measurement by X-ray. The
current paucity of (1) biomarker data from human OA clinical trials
(summarized in Table II), and (2) data on the role of biochemical
markers for monitoring the treatment of OA, can chieﬂy be ascribed
to the absence of therapies with structure modifying activity.
Without a structure modifying agent and a practically useful gold
standard for monitoring structural change, it is challenging toqualify a biomarker to be “ﬁt for purpose” for monitoring structural
modiﬁcation. Nevertheless, preclinical studies of disease-modi-
fying OA drugs (DMOADs) using biomarkers offer signiﬁcant
promise in terms of early indications of responses to treatment that
may translate into the clinic. Experiences with biomarkers in the
context of biologic therapies in rheumatoid arthritis offer promise
for OA in that short-term changes in serum levels of biomarkers
following initiation of therapy may predict long-term clinical and
radiographic outcomes17. These kinds of data need to be generated
in OA trials18,19.
Another issue regarding treatment monitoring using biochem-
ical markers is the heterogeneity of OA subsets. Results may differ
considerably between subsets with differences in pathobiology. OA
may be localized in one joint or generalized, hypertrophic with
osteophytes and subchondral bone sclerosis or atrophic, slowly or
rapidly progressing or showing no progression. Finally, a therapy
may act on OA through a variety of mechanisms and pathways. This
suggests that a biomarker may need to be speciﬁc for the particular
molecular target of the therapy in question. For instance, neo-
epitopes generated by collagenase activity could be sensitive to
collagenase inhibitors but not to drugs acting on proteoglycan
turnover. Even if a biomarker reﬂects the effects of a particular
therapy, it may not reﬂect all the mechanisms of action of the drug,
thus underestimating the therapeutic efﬁcacy or missing the
toxicity of the particular therapy. This means that the sensitivity of
change in a biomarker in a clinical trial may be dependent on the
characteristics of the population and the mechanisms of action of
the therapy. For these reasons, it would be advantageous to develop
a panel of biomarkers and use a wide variety of biomarkers during
the preclinical and clinical drug development processes.
Therapeutic trials
OA clinical trials are commonly focused on the investigation of
symptoms or structure modiﬁcation. In general, trial participants
fulﬁll the validated OA criteria of the ACR. In addition, trials of
symptom-modifying agents include patients whose disease is likely
to respond to treatment, for example those with at least moderate
intensity of symptoms (VAS 50 mm), and those with a ﬂare of
symptoms upon withdrawal of their standard therapy (ﬂare trials).
These trials are generally limited to 3 or 6-month follow-up.
Trials of structure-modifying agents include patients without
end-stage disease and often those with a perceived high risk for
structural progression, for example, middle age, overweight
women, although these traditional selection criteria are generally
poor for identifying risk of knee OA progression20,21. Structure-
modifying trials generally span 1e3 years. A series of disappointing
late-stage terminations of clinical trials investigating new potential
DMOADs has led to the call for a new development paradigm for
DMOADs, with a stronger focus on the biology of the joint and the
redesign of clinical trials to include new and more sensitive
biomarkers22.
One very important issue that is usually ignored in recruiting
patients for clinical trials is the phasic nature of OA in some patients
resulting in much variability in rates of disease progression. Some
patients with knee OA observed over prolonged periods (5 years)
may experience periods of progressive structural damage and then
relative inactivity23. Often non-progressors have been found to
predominate in OA clinical trials for disease modiﬁcation making
the detection of therapeutic efﬁcacy very difﬁcult if not impossible.
Importantly, there are a few studies that demonstrate the potential
ability to identify progressors using biomarkers thereby enabling
enrichment of trial populations with disease progressors as
opposed to non-progressors, and providing a signiﬁcant advantage
over existing practice18,19,24,25. In future, recruitment for clinical
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nities to enrich for progressors.
The Outcome Measures in Rheumatoid Arthritis Clinical Trials
(OMERACT)eOARSI consensus has recommended a core set of
clinical outcome measures that should be included in clinical trials
in OA. No OMERACTeOARSI guidelines have yet been developed for
the use of non-imaging in vitro biomarkers in clinical trials. The core
set of clinical items includes pain, physical function, patient global
assessment, and for studies of at least 1-year duration, joint
imaging26. It was subsequently found that successful trial designs
must include both absolute and relative change, as well as
measures of pain and function as primary domains27. Each of these
types of clinical outcome measures (pain, physical function, patient
or physician global responses), as well as imaging outcomes, can
serve as clinical trial endpoints and endpoints for biomarker
qualiﬁcation.
The success of biomarker qualiﬁcation on a structural modifying
endpoint depends critically on the performance and speciﬁcity of
the endpoint. Although the methodological limitations are well
recognized28, to date, assessment of the inter-bone distance and
loss of joint space on a plain radiograph of the hip or knee is the
only validated measure of OA progression recommended for use in
randomized clinical trials in OA. Unfortunately, the limitations of
the traditional clinical trial outcome, JSN, are considerable and have
hampered the qualiﬁcation of biomarkers as well as the registration
of DMOADs. To date, no therapeutic agent has met this deﬁnition,
and it remains unclear how best to identify structural outcomes,
whether by radiographs, MRI, biomarkers, or direct visualization
using arthroscopy or a combination of these approaches.
General limitations of JSN that hamper the qualiﬁcation of
biomarkers include the following:
 It is an indirect measure of the alterations in articular cartilage;
 It fails to measure a dynamic process;
 Assessment of knee OA is confounded by the presence of
meniscal lesions and meniscal extrusion29;
 Changes in the knee over time are small, and typically occur in
only a subset (progressor) of patients (mean estimated annual
JSN rate 0.13 0.15 mm/year for knee OA)30;
 It is poorly reproducible when measured from conventional
weight-bearing radiographs of the hip or especially, of the knee
in full extension;
 Apparent JSN can occur in the absence of structural changes
due to varying degrees of knee ﬂexion;
 Bone marrow and synovial abnormalities may go undetected;
 X-ray features appear only after deterioration of surrounding
hard and soft tissues;
 It is poorly correlated with joint function and pain.
A variety of methodological approaches have been proposed to
improve the reproducibility of the assessment of the joint space
width in randomized controlled trials (RCTs) including semi-ﬂexed
views31, and ﬂuoroscopically assisted protocols; it remains unclear
which approaches are preferable, or whether other imaging tech-
niques are preferable andmore promising. Among the new imaging
techniques, MRI is the most promising and a more sensitive
imaging modality for use in the immediate future. MRI allows
assessment of cartilage biochemical and biomechanical integrity. It
permits quantiﬁcation of cartilage volume and changes in cartilage
contour and can be tailored to assess pathological changes in
associated joint structures, and tissues including bone, synovium
(inﬂammation), ligament, menisci and muscle as well as effusions.
Correlations between serum biomarkers andMRI data have already
been reported for knee OA32. Moreover, a combination of MRI and
soluble biomarkers have recently been used to improve the abilityto identify patients at highest risk of knee OA progression over
either modality used independently33. MRI has not yet been rec-
ommended as a primary endpoint in structural modifying RCTs in
OA. A review of its potential, and recommendations regarding the
use of MRI for OA clinical trials, is the subject of a companion OARSI
FDA white paper.
Although the consensus reached at OMERACT 3 advocated
continued study of biological markers of bone and cartilage
degradation and repair, none was recommended for inclusion in
clinical trials. Nonetheless, in view of the duration required for
phase III structure-modifying trials, identiﬁcation of a surrogate
biomarker for use in earlier phase II trials could considerably
improve the safety, cost, and efﬁciency of clinical development
programs. Osteoporosis trials provide a good example in which
molecular biomarkers are increasingly used as adjunct
measures of effect before initiation of multi-year long phase III
trials34.
Biomarker applications in development of therapeutics
for OA
Qualiﬁed biomarkers of OA have the potential to greatly expand
the knowledge gained from preclinical and clinical trials of disease
modifying agents. The BIPEDS system classiﬁes potential OA
biomarkers into six categories and encompasses the array of
biomarkers that could be used for enhancing clinical trials. The
most immediate hurdle facing researchers wishing to test a poten-
tial DMOAD in humans is the lack of early information in a clinical
trial. In order to test a DMOAD, a trial must presently have a lengthy
follow-up, enroll many subjects and rely upon an insensitive
method of assessment of disease progression. The level of ﬁnancial
investment is daunting, resulting in a negative impact on research
and development. In this section, we consider how each category of
the BIPEDS classiﬁcation scheme could be used to improve clinical
trial design and outcome. We also address the challenges in
developing and qualifying such biomarkers for clinical use.
Burden of disease
Burden of disease biomarkers indicate the extent or severity of
disease and could be considered tools for the staging of the disease.
They reﬂect the state of the disease at the time of assessment, but
do not necessarily predict a likelihood of progression or change in
disease burden. A burden of disease biomarker is typically qualiﬁed
by comparison to a clinically deﬁned gold standard assessment
method. A burden of disease biomarker assessed locally, such as
from analysis of SF, would be expected to reﬂect the disease status
in a single joint, while assessment in blood or urine would more
likely indicate the extent of the disease in all joints as well as
normal physiology. Some molecular biomarkers, such as
biomarkers of cartilage turnover, can provide information on the
nature and extent of the current active process, but will not indicate
the level of tissue damage already accrued or its precise location.
Uses
 To provide a global measure of disease burden from all joints
and skeletal and soft tissue components thereof;
 Potentially to discriminate between mono- and poly-articular
OA;
 To identify patients with high burden of active disease for
inclusion into clinical trials of DMOADs expected to improve
later stage disease;
 To help identify patients with low burden of active disease but
with no or limited tissue alterations or structural alterations for
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progression of early OA;
 To balance treatment arms in a DMOAD trial for metabolic
activity or stage of disease that would not otherwise be obvious
from usual randomization criteria;
 To identify where in the body the burden of disease lies and
aid in patient stratiﬁcation, made possible when joint-speciﬁc
biomarkers or patterns of biomarker expression are
discovered.
Challenges
 Requires comparison to gold standard for qualiﬁcation, but
there is no clear gold standard;
 A biomarker may be more sensitive than imaging, picking up
a signal of early OA in asymptomatic joints with no obvious
imaging changes;
 Uncertainty about what level of burden of disease is the
optimal target for a DMOAD as early pathology may differ from
more advanced pathology;
 There may be molecular subsets of disease e a biomarker
might accurately reﬂect the burden of disease in one patient
but not another;
 The level of a biomarker may change with the disease
progression, such that some will be particularly elevated in
early phases and others in late phase;
 Due to the complex nature of the joint organ comprised of
different tissue types, a true burden of disease measurement
might require multiple biomarkers.Investigative
Investigative biomarkers are those that may not yet have
enough evidence accumulated to be assigned to a particular BIPEDS
category but nevertheless show sufﬁcient promise to be incorpo-
rated in drug research at early stages to determine utility for
subsequent use. In general, investigative biomarkers should be
included, along with better-qualiﬁed biomarkers, in preclinical
studies and clinical trials to advance our understanding of the
disease and drug and to provide opportunities for biomarker
development and qualiﬁcation.
Uses
 To explore novel biomarkers that could be informative in future
preclinical and clinical trials;
 To contribute to biomarker data packages that support quali-
ﬁcation of a biomarker or biomarker set for a particular
outcome;
 To further understand the pathobiology of OA;
 To further understand the mechanism of action of
a DMOAD.
Challenges
 Assays for investigative biomarkers might not bewell validated
and the data produced might not be robust;
 Conversely, investigative assays could produce highly repro-
ducible, robust data that turn out to lack speciﬁcity for the
molecular or tissue target;
 Clinical trials are not currently designed for testing of investi-
gative biomarkers, making it difﬁcult to achieve statistical
power for biomarker evaluation;
 Biomarkers studied in preclinical disease models might not
translate to human OA.Prognostic
A prognostic biomarker indicates whether a patient’s disease is
likely to progress and may also indicate how quickly the progres-
sion will occur. A prognostic biomarker may also provide an early
response to treatment that is prognostic of subsequent, much later,
clinical responses. Similarly, a prognostic biomarker could indicate
who is at risk for developing symptomatic OA. There is a need for
such markers since current clinical trials designed without the aid
of biomarkers, often contain a minority of progressors (mean
annual risk 6%, range 1e20% based on KL grade)30. Predictive
biomarkers, used to identify a subset of patients likely to respond to
a particular drug, constitute a particularly useful subset of prog-
nostic biomarkers. For instance, a threshold PGE2 level in SF might
correlate with the ability of a COX-2 antagonist to be effective in
that joint. Prognostic biomarkers include the largest variety of
biomarker types, including variant biochemical biomarkers and
invariant genetic biomarkers, although the latter may at some point
in the future be considered risk factors as opposed to biomarkers.
Uses
 To select subjects likely toprogress rapidly (‘high-risk’patients by
biomarker measurement) to reduce the length of time required
to see an effect of a DMOAD in a clinical trial thereby shortening
the trial and to improve the chances of observing efﬁcacy;
 To select subjects likely to progress rapidly (‘high-risk’ patients
by biomarker measurement) for purposes of stratiﬁcation;
 To increase the power of a trial to detect a signiﬁcant drug
effect with a limited number of subjects;
 To select subjects likely to progress rapidly (‘high-risk’ patients
by biomarker measurement) who would beneﬁt most from
therapy with structure modifying agents;
 To select subjects for primary prevention trials (screen for at
risk for developing OA to demonstrate reduction of incidence);
 To select patients likely to respond to a given drug for inclusion
in a clinical trial. For instance, patients with high levels of
a matrix metalloproteinase (MMP)-13 speciﬁc collagen
cleavage product could be selected for inclusion in a trial of an
MMP-13 inhibitor;
 As a companion diagnostic, to select likely responders for
treatment with a marketed product;
 To provide predictive evidence that disease processes have
been beneﬁcially impacted by serving as an early indicator of
a later trial outcome or response to therapy; this category of
markers would therefore form a speciﬁc subset of efﬁcacy
of intervention markers described below.Challenges
 The prognostic effect of a biochemical biomarker must be
distinguished from prognostic clinical (weight, injury) or
genetic variables that may inﬂuence biomarker levels;
 Qualiﬁcation of a prognostic biomarker would require a large,
long and ﬁnancially daunting prospective trial although this
challenge may be overcome with the use of legacy samples
from the many excellent existing OA epidemiology studies.
Efﬁcacy of intervention
Biomarkers of efﬁcacy of intervention can range from target
engagement and pharmacodynamic assays (which assess whether
the compound is hitting the desired target and is having the desired
downstream biochemical effects) to strict surrogate endpoints that
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of the disease. Slowly progressive diseases, such as OA, pose a range
of drug development challenges, particularly in phase II dose-
ﬁnding studies35. Target engagement and pharmacodynamic
biomarkers are likely to have the earliest impact on drug devel-
opment of all the BIPEDS biomarkers by inﬂuencing decisions on
dose selection and advancement of drugs to later phase trials.
While a surrogate biomarker would be highly desirable, the path to
generation and qualiﬁcation for a ‘characterization level’ biomarker
is likely to be shorter and provide beneﬁt to programs in the near
term at decision points in early preclinical studies and clinical trials.
In contrast, qualiﬁcation of a biomarker as a surrogate biomarker
will be a painstaking but highly valuable effort (see the section on
Pathways for Biomarker Qualiﬁcation).
Uses
 To demonstrate that a drug is having the desired immediate
downstream biochemical effect;
 To understand the pharmacodynamics of a drug intervention
and the relationship between pharmacodynamics and
pharmacokinetics;
 To provide a basis for the selection of lead candidates for
clinical trials;
 To contribute to the understanding of the pharmacology of
candidates;
 To characterize subtypes of disease for which a therapeutic
intervention is most appropriate;
 To choose a dose and dose schedule via ex vivo and in vivo
studies;
 To support an efﬁcacy endpoint;
 To support go/no go decisions in advance of preclinical and
clinical studies and trials;
 To serve as a surrogate biomarker for delay of structural
worsening, reduction of pain, or improvement in function.
Challenges
 For drugs administered intra-articularly to treat a single joint, it
may be difﬁcult to monitor efﬁcacy of intervention using
systemic biomarker assessments (blood or urine), particularly
if other joints are involved in OA;
 Qualiﬁcation as a surrogate biomarker is difﬁcult in the absence
of a gold standard;
 In order for a pharmacodynamic or target engagement
biomarker to be informative, it must be speciﬁc for the
mechanism of action of drug being assessed;
 A biomarker might provide an accurate assessment of target
engagement, but might not be related to clinical response.
Diagnostic
A diagnostic biomarker usually indicates whether an individual
has the disease or a speciﬁc subtype of the disease, but may not
reﬂect disease severity. It also has the potential to identify people at
risk for OA based on genetic or other considerations. A biochemical
biomarker could be more sensitive than an imaging marker, by
detecting the process leading to OA before it is detectable by
radiography or other imaging modalities.
Uses
 To select subjects with molecular pre-radiographic OA for
primary prevention trials;
 To identify patients with different disease subtypes; To identify individuals unlikely to have OA as controls in
caseecontrol studies.Challenges
 The processes in OA vary with time and may vary in nature,
although common pathobiology is identiﬁable. A single diag-
nostic biomarker may therefore not be informative in all
patients;
 Qualiﬁcation of a diagnostic biomarker requires a gold stan-
dard. A biochemical assay could potentially be more sensitive
than an imaging gold standard. The qualiﬁcation would then
depend on long term cohorts where the diagnosis can be
veriﬁed in follow-up;
 Given the insidious onset and slow progression of OA struc-
tural changes, it may take many years, patients, trials, and
dollars to achieve correlation between a biochemical
biomarker and disease. The National Institutes of Health/
National Institute of Arthritis and Musculoskeletal and Skin
Diseases/National Institute on Aging (NIH/NIAMS/NIA) Public/
Private Osteoarthritis Initiative is an example of an effort that
could contribute to this end of assessing the correlation
between biomarkers and OA.
Safety
There exist important opportunities to use biomarkers to detect
pathological changes and cytotoxicity. Safety biomarkers could be
used in preclinical and clinical applications to monitor the health of
the joint tissues, thewhole joint organ, or the skeleton in general. For
instance, biomarkers reﬂecting the synthesis of the main proteins of
the joint might provide an index of the “joint-protective” effect of
a potential treatment. There are currently no studies exploring
speciﬁcally this aspect of joint tissue related biomarkers. Potential
complications obviously exist with regard to discriminating toxic or
pathological effects from beneﬁcial effects in the case of skeletal
biomarkers. In the absence of contrary evidence, increased cartilage
degradation or decreased synthesis of cartilage based on biomarker
data would be considered as potential “red ﬂags” in any treatment
regimen. A special circumstance is represented by repair, exempliﬁed
by collagen ﬁbrillogenesis, where molecules catalyzing and
enhancing this process, may instead prevent ﬁbril formation and
hamper repair when produced in relative excess36,37.
In contrast, there are emerging examples of toxicity monitoring
in OA trials with biomarkers of other organ systems. A notable
recent example is provided by the pilot trial of Brune 200938
wherein N-terminal pro-B-type natriuretic peptide concentra-
tions were shown to predict the risk of cardiovascular adverse
events fromNSAIDs and glucocorticoid rescuemedications in a trial
of an MMP inhibitor for OA. We anticipate that this will be
a growing area that will enhance the goal of personalized medicine
and patient safety. Clearly, a broad spectrum of biomarkers will be
necessary for a full safety assessment. The safety biomarkers should
also be chosen to demonstrate any effects on other similar struc-
tural anatomical elements, e.g., tracheal cartilage, intervertebral
disc, and rib, to name a few.
Uses
 To support other more generalized organ system safety indi-
cators in preclinical and clinical trials;
 Tomonitor for local and systemic adverse effects both early and
advanced;
 To set therapeutic dosages that do not impact on physiology.
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 Understanding what ‘safe’ ranges are for joint tissue
biomarkers;
 Safety biomarkers will need to be qualiﬁed against accepted
clinical standards, including pain assessments, functional
testing, and imaging;
 The safety threshold for each biomarker might be different
across individuals.
Summary
With the BIPEDS scheme, the biomarkers that are likely to have
the earliest beneﬁcial impact on clinical trials fall into two general
categories. The ﬁrst are those that will allow us to target trials to
subjects that are likely to either respond and/or progress within
a short time frame. For instance, a patient population with high
levels of an MMP-13 cleavage product, but without end-stage
cartilage loss, would be ideal for a trial with an MMP-13 inhibitor.
The second category of biomarkers includes those that provide early
feedback for preclinical decision-making and for trial organizers
that a drug is having the desired biochemical effect. This category of
biomarkers is particularly desirable in chronic diseases, such as OA,
where clinical outcomesmay take years to present39. In some cases,
the biomarker might be sufﬁciently qualiﬁed that the researchers
have conﬁdence in using it to justify advancement to phase 2 trials
and to determine a dosing schedule. These two categories reduce
the burden and risk of early stage trials by delivering essential early
information, making OA a more manageable and therefore a more
attractive target for drug developers.
Qualiﬁcation of known OA biomarkers
Biomarker validation vs qualiﬁcation
The validation and qualiﬁcation of a biomarker are two essential
processes involved with assessing the level of conﬁdence in
a speciﬁc biomarker. For scientists who develop new biomarkers,
validation means assessing all technical aspects of a speciﬁc assay
to address the following question: “Under what conditions can we
trust this assay and what it tells us?” Conversely, qualiﬁcation
consists of assessing the clinical value of a speciﬁc assay and
answers the question: “Is this marker useful for learning more
about the disease pathobiology or the efﬁcacy of the treatment
tested?” Currently there are no biomarkers that have been formally
qualiﬁed and cleared by the FDA for OA-related outcomes.
Validation
Standard laboratory-based biomarker assays are typically
quantitative in nature. Analytical validation of a speciﬁc quantita-
tive assay is usually established by ﬁve tests: intra- and inter-assay
variation, dilution recovery, determination of the detection and
quantiﬁcation limits and spiking recovery, although this latter test
is often not performed, especially when standards are synthetic
peptides. In addition, the stability of the biomarker (with storage
and freezeethaws) and key reagents should be established to
determine the parameters and stringency of storage necessary to
assure reliability of measurements. The exact assay validation
process will depend on the intended use of the assay, with assays
for surrogate markers undergoing more rigorous validation than
assays for exploratory endpoints. Not all biomarker assays are
“deﬁnitive” quantitative measurements. Some biomarker assays
generate “relative” results, due to the nature of the reference
materials or sample matrix39. One example would be genomic data
generated from microarray analysis of RNA. For these sorts ofrelative quantitative assays it is appropriate to place greater
emphasis on relative and temporal changes in biomarker concen-
trations rather than the absolute concentrations. Another example
would be an Enzyme Linked Immunosorbent Assay (ELISA) that
uses a crude extract as standard and for which biomarker results
are reported in arbitrary units. For these sorts of assays, the avail-
ability and sharing of a common international standard for
normalization is highly desirable.
In contrast to quantitative biomarkers, qualitative biomarkers
are discrete (discontinuous) and reported in either ordinal or
nominal formats. An example of a qualitative assay would be
a method to detect the presence of a single nucleotide poly-
morphism or gene mutation in a sample of DNA39. Assay validation
for a qualitative assay is more limited than for a quantitative assay
since concepts such as precision and dilutional recovery are not
relevant39. Just as important as pre-study method validation is in-
study validation (run acceptance), appropriate control samples and
run/sample acceptance criteria should be incorporated into the
analytical method for each assay to ensure quality data.
The speciﬁcity of the antibody(ies) used in the immunoassay is
a very important factor, although this has not been carefully inves-
tigated for most biomarkers. Indeed, recognition and cross-reactivity
experiments are usually performed using synthetic peptides or in
vitro generated degradation fragments, which are probably of
a different structure than the native immunoreactive forms detected
in biological ﬂuids. To date, published results of the structure of the
immunoreactive form have only been partly determined for one OA-
related biomarker, TIINE, which involves type II collagen cleavage by
collagenase40. This information can be difﬁcult to generate because
the concentrations of the analytes found in serum and/or urine are
usually very low and their determination requires complex analysis.
This aspect of the biomarker validation process is however of critical
importance for correct interpretation of biomarker results41.
Other critical information is that which concerns the tissue and
site(s) of origin of the biomarker. Incorrect assumptions regarding
tissues of origin have led to misinterpretation of biomarker data.
Mistakes of this kind may in part account for lack of correlation
between clinical and biomarker outcomes.
The Standards for Reporting of Diagnostic Accuracy (STARD)
statement42 has provided a checklist of speciﬁc information about
biomarker measurement, and the subjects tested, that should be
provided in any study validating a biomarker regardless of its
intended use. These include the following speciﬁc requirements
(summarized by Felson et al.43): to blind those measuring the
biomarker as to disease status (in a study of prognosis, this would
mean blinding to progression status); to deﬁne the rationale for and
selection of cutoffs differentiating ‘normal’ from ‘abnormal’
biomarker levels; and importantly, to note the source of subjects in
a study, reporting whether they were selected because of their
biomarker status or unique clinical ﬁndings.
Qualiﬁcation
Previously, the process of linking a surrogate endpoint to
a clinical endpoint has been referred to as validation or evaluation2.
However the use of the term validation has now been conﬁned to
the assessment of the performance characteristics of a biomarker
assay, while linking a biomarker to a clinical endpoint is referred to
as qualiﬁcation44. The use of biomarkers as surrogate endpoints in
a clinical trial requires the qualiﬁcation of the biomarker for speciﬁc
clinical endpoints (such as pain, loss of mobility, or need for a total
joint replacement) in a speciﬁc populationwith a particular disease
state and/or in the context of a speciﬁc class of therapeutic inter-
vention (adapted from Ref.2). Loss of mobility and total joint
replacement occur only after a very long time in most patients
(Fig. 2), and vary by nation and region due to differences in patient
Fig. 2. Conceptual framework for biomarker qualiﬁcation.
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time needed to qualify a biomarker, studies use structural
endpoints derived from X-ray and more recently from MRI.
For drug development, ‘efﬁcacy of intervention’ (‘E’ of BIPEDS)
biomarkers are sought. In theory, the optimal efﬁcacy of interven-
tion biomarker would be a perfect clinical outcome surrogate. In
the case of the perfect surrogate:
 The effect of the intervention on the surrogate predicts the
effect on the clinical outcome;
 The surrogate is in the only causal pathway of the disease
process;
 The intervention’s entire effect on the true clinical outcome is
mediated through its effect on the surrogate;
 The surrogate fully captures the treatment effect.
In reality, it is likely that few if any biomarkers will ultimately
achieve surrogate status let alone perfect surrogate status. Several
different methods have been proposed for quantifying the strength
of the surrogate45. This method provides a quantitative score for
a biomarker. Wagner et al. categorize the strength of a surrogate
based on four levels1: Exploratory, Demonstration, Characterization
and Surrogate biomarkers (summarized in Pathways for Biomarker
Qualiﬁcation-Levels of qualiﬁcation of biomarkers for drug devel-
opment use). This mark of the strengths of surrogacy is used in this
document.
As the Wagner classiﬁcation implies, robust linkage of
a biomarker with a clinical endpoint is not essential in early clinical
development when the goal is conﬁrmation of pharmacologic
activity or optimization of dose regimens2. As stated by the
Biomarkers Deﬁnitions Working Group in 2001: “Reliance on
a biomarker early in the drug development process, for instance for
candidate selection, entails the hazard that failure of a biomarker
may lead to the elimination of potentially effective agents. On the
other hand, substantial evidence that a biomarker will predict
clinical beneﬁt or risk is needed when use of the biomarker as
a surrogate endpoint is proposed as the basis for regulatory
approval. In this case, erroneous decisions based on invalid surro-
gate endpoints may have broad public health consequences”2.
Qualiﬁcation endpoints for OA biomarkers
As described above, there are many possible qualifying
endpoints for an OA-related biomarker including signs (inﬂam-
mation) and symptoms (pain), structure or functional outcomes in
OA. A biomarker could be qualiﬁed for different stages of OA such
molecular, pre-radiographic, or radiographic stages of OA. In
theory, a biomarker could be qualiﬁed for an outcome in a speciﬁc
joint if the biological ﬁndings supported such speciﬁcity. We are
only beginning to appreciate cartilage matrix biochemistry in this
level of detail as exempliﬁed by the differences in matrix
biochemistry and response to injury of ankle vs knee cartilage46. In
practice, the qualiﬁcation process is an empiric and gradual one,correlating changes in a biomarker with change in state of a joint(s).
To date the process of biomarker qualiﬁcation has tended to relate
a biomarker to a speciﬁc tissue component of the whole joint organ
such as bone, cartilage or synovial tissue.
Sources of biomarker variability
Biochemical markers in blood and urine provide information on
systemic skeletal tissue turnover47 and are not necessarily speciﬁc
for the alterations occurring in the signal joint48. For example, it has
been shown that degenerative disease of the knees, hips, hands and
lumbar discs contributed independently and additively to urinary
CTX-II levels illustrating the total body contribution to systemic
levels48,49. The potential contribution of intervertebral discs is of
particular relevance because disc degeneration is common in aging.
Systemic biomarker levels cannot be assumed to reﬂect total body
OA burden based on radiographic damage or cartilage volume
estimated by quantitative MRI because these factors alone do not
fully account for the differential contribution of soluble biomarkers
from different joints50. Serum and urinary levels of most markers
also vary with gender, age, menopausal status, ethnicity, and OA
risk factors such as body mass index. Speciﬁc examples include the
effects of gender, ethnicity and age on COMP51,52 and the effect of
BMI on CPII53.
Biomarker levels can also be inﬂuenced by other skeletal alter-
ations, such as osteoporosis or by concomitant medications. It is
likely that differential processing by the liver or kidneys occurs
before systemic biomarkers reach a steady state in body ﬂuids, and
this metabolism may not occur reproducibly in all patients,
particularly in the presence of systemic disease54,55. Measurements
in urine require correction by creatinine to adjust for variability
related to hydration and renal status. One of the main factors
affecting pre-analytical variability is diurnal change. Themagnitude
of diurnal-related changes in the concentration of seven markers
(serumHA, COMP, KS-5D4, TGFß1, CPII, and urinary CTX-II and C2C)
has been shown to be greater than the analytical inter- and intra-
assay related variability, indicating that the diurnal-related varia-
tionwas predominantly a result of biological variability rather than
assay variability56,57. For the biomarkers found to be signiﬁcantly
associated with radiographic severity (serum COMP, KS-5D4, C2C,
C1, 2C, and urinary CTX-II), the biomarker concentrations at the T2
or T3 time points showed the most consistent correlation with
radiographic knee OA when the sampling was performed during
the afternoon (T2) and the early evening (T3). A study on serum
PIIANP and serum HELIX-II concluded that concentrations of these
two markers increased signiﬁcantly from T0 (before arising from
bed) to T1 (1 h after arising)58. It was also shown that serum CTX-I
and serum HA markers levels are markedly inﬂuenced by food
intake which also does increase intra-subject variability59. These
and other data (prior biomarkers white paper http://www.oarsi.
org/index2.cfm?section¼OARSI_Initiatives&content¼Biomarkers)
provide a rationale for standardization of sample collection
procedures for OA clinical trials.
Table Ia
Sample sizes to achieve 80% and 90% power to detect assumed differences between
two parallel groups
Number of
patients/group
required
for 90% power*
Number of
patients/group
required for
80% power*
Underlying
treatment
difference to
detect
SD
(between-
subject)
Effect size
(difference/SD)
15 12 1.84 1.5 1.23
30 23 1.28 1.5 0.85
60 45 0.90 1.5 0.60
100 76 0.69 1.5 0.46
15 12 2.45 2.0 1.23
30 23 1.70 2.0 0.85
60 46 1.19 2.0 0.60
100 76 0.92 2.0 0.46
* Based on 2-sample t-test (2-sided, alpha¼ 0.05) for difference between groups
with null hypothesis that treatment difference¼ 0.
Table Ib
Sample sizes to achieve 80% and 90% power to detect assumed underlying ratio of
treatment effect between two parallel groups
Number of
patients/group
required for
90% power*
Number of
patients/group
required for
80% power*
Underlying mean
ratio between
groups to detect
CV (SD/Mean) in
original scale
114 85 0.65 1.3
165 124 0.70 1.3
253 189 0.75 1.3
418 313 0.80 1.3
80 60 0.65 1.0
116 87 0.70 1.0
177 133 0.75 1.0
294 220 0.80 1.0
47 35 0.65 0.7
67 51 0.70 0.7
103 77 0.75 0.7
170 127 0.80 0.7
* Based on 2-sample t-test (2-sided, alpha¼ 0.05) for ratio of treatment effect
between groups with null hypothesis that ratio¼ 1, and common CV.
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dietary supplements onbiomarker levels. As described above, serum
hyaluronan showed signiﬁcant variation related to food consump-
tion in healthy volunteers60 and circadian variation of CTX-I was
found to be reduced by fasting61, suggesting that fasting can have
a signiﬁcant effect on the circadian variation of markers of bone
resorption. Gordon et al. 200857 showed that urinary CTX-II was not
affected by food consumption or physical activity and may offer an
advantage in the context of clinical trials incorporating morning
body ﬂuid sampling. Clearly, pre-analytical factors contribute to
intra- and inter-assay variability of biochemical markers levels and
consequently need to be investigated and controlled as tightly as
possible. Taken together, these studies point to the need for stan-
dardization of sample collection within a trial to minimize non-
treatment related variation. Recommended methods of sample
acquisition, handling and storage are provided in Appendix A.
Summary of OA biomarkers
Biochemical markers of bone and cartilage turnover are pres-
ently the most advanced with respect to matrix remodeling35.
Several excellent recent reviews provide a summary of biomarkers
in general and several summarize the data to support classiﬁcation
into one or more of the particular BIPEDS categories35,62e68. In this
section, we focus on “soluble biomarkers” studied to date in human
OA clinical trials, and not genetic/genomic or imaging biomarkers
or biomarkers studied in the absence of an intervention. Although
a few soluble biomarkers are quantiﬁed by mass spectroscopy
approaches, most are currently assessed by immunoassay. Tables Ia
and b provide a look at the sample sizes required for biomarker
studies. Table II presents data for all known peer-reviewed publi-
cations to date of pharmacologic OA trials with either structural or
clinical trial outcomes that included published biomarker analyses,
and an indication of the success or failure of the trial for the
primary and biomarker outcomes. The reported assay coefﬁcients
of variation (CVs) are provided when they were reported, which
may be helpful for assessing needed sample sizes for future studies.
In addition, the reported concentrations [and standard deviations
(SDs) when available] before and after treatment are listed to begin
to provide a benchmark for comparison across studies, albeit
limited at the present time. Table III provides a summary of the
known tissue sources and current BIPED classiﬁcation for many of
the most common and best-qualiﬁed OA-related biomarkers.
Statistical issues and sample size estimates for biomarker studies
Table Ia provides a look at the sample sizes required if the
between-subject variability (SD) increases from 1.5 to 2.0 or the
power desired changes from 90% to 80% given the same treatmentdifferences. Biomarkers are often not normally distributed due to
the potential for a high incidence of values below the limit of
quantiﬁcation. To normalize the distribution the values are usually
log-transformed and Table Ib provides some sample size estimates
when the biomarker is expressed as ratio or percent differences and
analyzed on the log scale. In the papers summarized in Table II
(below) and others (reviewed by van Spil et al.62), many
biomarkers, such as those measured by radiography, e.g., JSN, were
explored for their ability to predict the progression of OA or to
change concurrently with OA. However, results were generally not
consistent across the studies for multiple reasons: large variability
of the assays, unpredictable variability of the biomarkers, under-
powering of the study, or slow progression of OA were the most
often cited reasons for non-signiﬁcant or inconsistent ﬁndings.
The under-powering of the studies was generally due to the fact
that the biomarkers were regarded as exploratory endpoints or the
basis for subgroup analyses, hence, were not powered sufﬁciently
at the planning stage. Some studies were designed as pilot studies,
which relied on detecting statistical signiﬁcance instead of mean-
ingful difference as a measure of the importance of the biomarker.
These types of studies serve the purpose of hypothesis generation;
however, as experiences with the biomarkers accumulate, an
organized effort is necessary to deﬁne the following elements so
that standards can be established for future studies against which
to benchmark:
1. Identify clinically meaningful differences between two active
treatments or between an active treatment and placebo with
respect to validated clinical endpoints.
2. Deﬁnemeaningful correlation between the biomarkers and the
clinical endpoints, i.e., how large the magnitude of the corre-
lation has to be.
3. Deﬁne the meaningful difference between two active treat-
ments or between an active treatment and placebowith respect
to the biomarker once it is demonstrated to correlate with the
clinical endpoints.
Consideration of these three elements is important to ensure
sufﬁcient numbers of subjects in the study, and hence, sufﬁcient
power to detect the underlying meaningful difference based on
biomarkers. They also prevent statistical signiﬁcance being reached
only because of the large sample sizewhilemeaningful difference is
not observed. A critical component for the success of these aims
will be the establishment of clinical meaningful endpoints related
Table II
Summary of biomarker data generated in OA clinical trials to date
Trial e intervention
(duration)
Study ref Patient numbers Sample type CV% (biomarker
units)
Treatment Placebo Comments Assay/cut-points
Pre Post Pre Post
Ibuprofen 2400
mg qd for
knee pain 
4e6 w (E)
Gineyts
200470
Human 156/45 NF morning urine uCTX-II (E) <10% (ng/mmol Cr) 225 2.16 229 2.06 226 1.88 265 2.06 Patients with high
levels were
responsive to
therapy
C-ELISA Cartilaps e
Christgau 200171
uGlc-Gal-
PYD (⌀E)
<11% (nmol/mmol Cr) 6.0 1.5 6.2 1.5 5.7 1.4 6.3 1.4 HPLC Gineyts 200172
Glucosamine
sulphate
1500 mg/d
 3 y (E)
Christgau
200418
Human 106/106
[n¼ 61 above
1 SD cut-off]
NF second morning
void urine
uCTX-II/Cr
(E)
8.4% (ng/mmol) All: 216.5 9 at
baseline
All: Loss of joint
space (0.06 mm)
over 3 years
All: 219.5 9
at baseline
Loss of joint
space (0.31
mm) over
3 years
C-ELISA Cartilaps
with mAb F46 per
Christgau 200171;
High turnover group
deﬁned as baseline
261.3 (i.e., 1 SD
above mean of
169.1 92.3 in
reference population)
High turnover
group mean
413 28
High turnover
group mean 336 26
[Gain of joint space
(0.083 mm; P¼ 0.07)
over 3 years; Global
WOMAC decreased
24.5%]
High turnover
group mean
375 33
High turnover
group mean
411 252
[Loss of joint
space (0.44
mm) over
3 years; Global
WOMAC
decreased 4.5%]
Promising approach;
larger sample
size (>61) of high
turnover patients
likely needed for
statistical
signiﬁcance
For high turnover
group: change in
uCTX-II from
baseline to 12 m
correlated with
average joint space
width loss over
3 years (r¼ 0.43;
P< 0.05)
For high turnover
group: change in
uCTX-II from
baseline to 12 m
correlated with
average joint space
width loss over
3 years (r¼ 0.27;
P< 0.03)
Salmon calcitonin
(oral) 0.5e1.0
mg/d  48d
for knee OA
patients
with positive
knee bone
scans (E)
Manicourt
200673
Human 27/14 F serum & second
morning void
between 9 and 11
AM [all median
values reported
show baseline
and day 84 values]
uCTX-II/Cr (E) <6% (ng/mM) 395 290 368 370 ELISA Cartilaps e
Nordic Bioscience
(Herlev, Denmark)
sHA (E) <6% (mg/ml) 61 48 60 69 ELISA method of
Manicourt 1999
sC2C (E) <6% (ng/ml 30 23 27 30 ELISA-IBEX
(Montreal, CA)
uNTX-I/Cr (⌀E) <4% (BCE mM/
mM Cr)
48 43 57 56 ELISA-OSTEX Intl
(Seattle, WA)
sOC (⌀E) <9% (ng/ml) 12 16 18 16 ELISA BioSource,
(Nivelles, Belgium)
sMMP-1 (⌀E) <8% (ng/ml) 8 9 8 9 ELISA-GE Healthcare
(Little Chalfont, UK)
sMMP-3 (E) <5% (ng/ml) 20 19 19 24 ELISA-GE Healthcare
(Little Chalfont, UK)
sMMP-8 (⌀E) <5% 5 5 4 4 ELISA-GE Healthcare
(Little Chalfont, UK)
sMMP-13 (E) <5% (pg/ml) 100 64 52 76 ELISA-GE Healthcare
(Little Chalfont, UK)
sTIMP-1 (⌀E) <5% 173 184 151 149 ELISA-GE Healthcare
(Little Chalfont, UK)
TIMP-2 (⌀E) <5% 11 11 18 14 ELISA-GE Healthcare
(Little Chalfont, UK)
BRISK study:
Risedronate
5 mg/d or
15 mg/d 
12 m (⌀E for
JSN, E for
WOMAC)
Spector
200574
Human F early morning
urine and serum
uCTX-II (ng/mmol Cr) (E) 340.1 (24.0) 22.8 5.35%
(15 mg)
312.5 (19.9) 14.5 5.4%
(15 mg)
ELISA Cartilaps e
Nordic Bioscience
(Herlev, Denmark)
uNTX-1 (nmol/mmol Cr) (E) 38.6 (2.2) 32.9 4.92%
(15 mg)
40.3 (2.8) 17.2 4.9%
(15 mg)
ELISA Osteomark-
OrthoClinical
Diagnostics (High
Wycombe, Bucks, UK)
sAlk Phos
(bone speciﬁc)
NR NR 29.1 2.6%
(15 mg)
NR 2.7 2.5%
(15 mg)
ELISA Ostase-
Beckman-Coulter
(San Diego, USA)
(continued on next page)
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Table II (continued )
Trial e intervention
(duration)
Study ref Patient numbers Sample type CV% (biomarker
units)
Treatment Placebo Comments Assay/cut-points
Pre Post Pre Post
Chondroitin
sulfate 
1 y (E)
Uebelhart
199893
Human 21/19 (21/20
for sOC but 23/23
overall)
NF serum & second
morning void urine
sKS (E) NR (ng/ml) 449 119 420 100 386 133 403 142 C-ELISA with mAb
1/20/5-D-4 Method
of Thonar 198480
uPYD/Cr (E) NR (nmol/L/mmol 56 25 53 19 59 40 70 30 RP-HPLC Uebelhart
199094
uDPD/Cr (E) NR (nmol/L/mmol) 7.7 3.0 7.7 2.3 8.5 5.4 11.7 8.1 RP-HPLC Uebelhart
199094
sOC (E) NR (ng/ml) 16 7 16 6 21 13 26 29 RIA, ELSA-OSTEO
CisBiointernational,
Gif/Yvette, France
Intra-articular
hyaluronan 
5 weekly
injections
Hasegawa
200895
Human 28
(all treated)
SF time not
speciﬁed
sfKS (E) NR (nmol/ml) 61.2 35.8 52.8 25.3 ND e no vehicle control HPLC Method of
Yamada 200096
sfC6S (E) NR (nmol/ml) 19.1 6.7 17.8 6.1 ND e no vehicle control HPLC Method of
Yoshida 198997 &
Shinmei 199298
sfC4S (E) NR (mg/ml) 6.1 3.7 5.2 2.9 ND e no vehicle control
sfTenascin-C (⌀E) NR (ng/ml) 37.4 59.1 39.0 58.1 ND e no vehicle control ELISA e IBA
(Gunma, Japan)
Supplemental
soy protein
40 g/d 
3 m (E)
Arjmandi
200499
Human 44/44 F serum YKL-40 (E in men) 6.8% (ng/ml) All: 89.9 7.6;
men: 91.0
10.3; women:
93.4 11.4
Change
(decrease) in
YKL-40 from
baseline to 3
months only
signiﬁcant in
men (compared
to placebo)
All: 67.8 6.3 men:
71.3 10.2; women:
64.6 7.8
Increased in
all groups
Clinical and biomarker
effects in men, not
women
S-ELISA-Metra
Biosystems
(Mountain
View, CA)
IGF-1 (E in men) 7.6% (ng/ml) All: 113.3 8.2;
men: 125.0
10.7; women:
97.6 12.9
Change (increase)
in IGF-1 from
baseline to 3
months only
signiﬁcant overall
and in men, not
women (compared
to placebo)
All: 135.6 10.6;
men: 158.7 14.8;
women: 107.9 9.3
Increased in
all groups
Clinical and biomarker
effects in men, not
women
Radioimmunoassay-
Diagnostic Systems
Labs Inc (Webster, TX)
F¼ fasting; NF¼ non-fasting; h¼ hour; d¼ day; bid¼ twice daily; w¼week; m¼month; y¼ year; pAb¼ polyclonal antibody; LC-MS/MS¼ liquid chromatography followed by low then high energy mass spectroscopy;
RP¼ reversed-phase; HPLC¼ high pressure liquid chromatography; s¼ serum; p¼ plasma; u¼ urine; c¼ cartilage; NR¼ not reported; S-ELISA¼ sandwich-ELISA; C-ELISA¼ competitive (inhibition)-ELISA.
(E) means showed evidence for change with intervention and (⌀E) means no evidence of statistical difference of biomarker with intervention (did not meet efﬁcacy of intervention criteria); when the trial produced disease
modiﬁcation an (E) is listed in the ﬁrst column.
CTX-II¼ carboxy-telopeptide of type II collagen; COMP¼ cartilage oligomeric matrix protein; HA¼ hyaluronan; C2C¼ collagenase-generated neoepitope of type II collagen; C1, 2C¼ collagenase-generated neoepitope of types I
and II collagens; TIINE (mAbs 9A4/5109) ¼ type II collagen neoepitope; CPII/PIICP¼ type II collagen carboxy-propeptide; Col2-3/4m¼ type II collagen denaturation epitope; KS¼ keratan sulfate; CS-846¼ aggrecan chondroitin
sulfate 846 epitope; NTX-I¼N-telopeptide of type I collagen; CTX-I¼ carboxy-telopeptide of type I collagen; PYD¼ pyridinoline; DPD¼ deoxy-pyridinoline; OC¼ osteocalcin; Glc-Gal-PYD¼ glucosyl-galactosyl-pyridinoline; C4S and
C6S¼ chondroitin-4 and -6
sulfate; Tenascin-C; YKL-40¼ human cartilage glycoprotein 39; IGF-1¼ insulin growth factor-1; MMP¼metalloproteinases: -1 (collagenase-1), -3 (stromelysin), -8 (neutrophil collagenase), -13 (collagenase-3); TIMP¼ tissue
inhibitor of metalloproteinase: -1 or -2; TGF-ß1¼ transforming growth factor-ß1; Alk Phos¼ alkaline phosphatase.
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Table III
Recommended panel of informative commercially available OA-related biomarkers qualiﬁed for various OA outcomes*
Biomarker Processy (preliminary) Tissues of origin (see
discussion below Table)
BIPEDS
classiﬁcationsy
Surrogacy based on human
clinical trials (preliminary)
ELISA assay type
Urinary CTX-II Type II collagen degradation,
osteophyte burden of
disease
Mineralized and non-
mineralized cartilage,
growth plate cartilage,
bone
Knee: BPED
Hip: BPD
Characterization: changed signiﬁcantly
in three pharmacologic trials that met
primary clinical endpoints18,70,73
Competitive-inhibition for
human urinary samples
and sandwich for animal
serum samples
Serum COMP Cartilage degeneration Cartilage > tendon,
meniscus, synovium,
osteoblasts, arterial wall
Knee: BPD
Hip: BPD
Exploration: not used to date in
published pharmacologic trial
Competitive-inhibition &
sandwich
Serum HA Osteophyte burden of
disease and synovitis
Cartilage, meniscus,
synovium and
ubiquitous in body
Knee: BPED
Hip: P
Demonstration: changed signiﬁcantly
in one pharmacologic trial that met
primary clinical endpoints73
Sandwich protein binding
assay
Serum and urine
C1, 2C
Types I and II collagen
degradation
Cartilage, bone,
synovium, etc.
Knee: D(u)
Hip: none
Exploration: non-signiﬁcant change
in one pharmacologic trial that met
primary clinical endpoint73,91
Competitive-inhibition
Serum and urine
C2C
Type II collagen
degradation
Cartilage Knee: E(s), D(u)
Hip: B(s)
Demonstration: changed signiﬁcantly
in one pharmacologic trial meeting
primary clinical endpoints73
Competitive-inhibition
Serum and urine
Coll2-1 and
Coll2-1NO2
Type II collagen
degradation
Cartilage Knee: D(s), B(u),
P(u)
Hip: D(s)
Exploration: not used to date in
published pharmacologic trial
Competitive-inhibition
Serum CPII or
PIICP
Type II collagen
synthesis
Cartilage Knee: D(s)
Hip: B(s)
Exploration: non-signiﬁcant change
in one pharmacologic trial that met
primary clinical endpoint91
Competitive-inhibition
PIIANP Type II collagen
synthesis
Cartilage Knee: BPD
Hip: none
Exploration: not used to date in
published pharmacologic trial
Competitive-inhibition
Urine/serum
NTX-1
Bone resorption Bone turnover Knee: P(u), E(u)
Hip: P(s)
Demonstration: changed signiﬁcantly
in one pharmacologic trial that met
primary clinical (WOMAC) endpoint74
Competitive-inhibition
Urine/serum
CTX-1
Bone resorption Bone turnover Knee: B(u),
D(s/u), P(u)
Hip: none
Exploration: not used to date in
published pharmacologic trial
Competitive-inhibition
Serum CS846 Cartilage aggrecan
synthesis/turnover
Cartilage Knee: P
Hip: none
Exploration: non-signiﬁcant change
in one pharmacologic trial that met
primary clinical endpoint91 but
changed associated with
concurrent JSN
Competitive-inhibition
Serum MMP-3 Protease stromelysin
involved with joint
tissue degradation and
inﬂammation
Synovium,
cartilage
Knee: E
Hip: none
Characterization: changed signiﬁcantly
in two pharmacologic trials that met
primary clinical endpoints73,88
Sandwich for total MMP-3
assay
PIIANP¼ type IIA procollagen amino propeptide; see footer Table II for additional abbreviations.
* This list does not include many emerging biomarkers that may prove useful in the future nor cytokines and chemokines that are also worthy of consideration.
y These are general recognized processes for which these biomarkers are known. This is very preliminary information at this time and should not be considered deﬁnitive
but rather in evolution. This information is derived from van Spil62; Cibere 200915; Conrozier 2008101; Kraus 201050. References in Table as follows:18,70,73,74,88,90.
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qualifying endpoints for biomarker studies.
Le Graverand, et al. 200669 had also suggested the possibility
that no single biomarker is sensitive enough to serve as a surrogate
for radiographic outcomes in OA, but the combination of multiple
biomarkers, representing different aspects of articular cartilage
biochemistry, may signiﬁcantly improve the detection and predic-
tion of radiographic changes of knee OA. A natural extension of the
three elements stated above, therefore, is to identify groups of
biomarkers that are correlated with each other and that, in
combination, have good predictive value for the progression of OA
or change concurrently with radiographic outcomes.
Summary of biomarker data generated in OA clinical trials
A few details are worth noting regarding the use of biomarkers
in published clinical trails. In 137 individuals with knee OA, no
signiﬁcant difference was seen between patients in the placebo or
glucosamine sulfate treated groups with respect to the ratio of
markers of collagen type II breakdown (lnC1, 2C/C2C) in serum or in
urine81. This study used ﬂare/no ﬂare status as the clinical endpoint.
In a study of 201 patients with inﬂammatory knee OA, a decrease in
the levels of urinary Glc-Gal-PYD was observed following treat-
ment with the nonsteroidal anti-inﬂammatory drug ibuprofen butnot with placebo70. Finally, a group of 35 patients with OA were
randomly selected to receive a potent inhibitor of MMP-3 (BAY 12-
9566) or placebo. Levels of the aggrecan 846 epitope were higher in
the treated group compared to the control group implying that
aggrecan synthesis improved84. This study used an original
protocol, measuring markers directly in the cartilage samples
obtained at the time of surgery 3 weeks after the start of treatment.
The advantage of such an approach is direct analysis of cartilage,
short duration of treatment, and small numbers of patients.
Most past studies have used structural and/or clinical endpoints
to investigate the usefulness of a biomarker. A 30-month study of
a subset (60 progressors and 60 non-progressors) of the patients in
a clinical trial assessed by radiography (progression limit: JSN
0.33 mm) showed a reduction of JSN in the doxycycline treatment
group but a paradoxical increase in uTIINE with treatment92. In
a study testing the effects of risedronate on 1885 patients suffering
from knee OA, CTX-II levels decreased with risedronate in patients
with knee OA although there were no differences in the traditional
JSN radiologic outcome or in symptoms in response to the treat-
ment. There was however a dose-related preservation and
improvement in tibial subchondral bone architecture100 with
treatment. The utilization of more sensitive imaging methods such
as MRI, in future clinical trials, may clarify and resolve such
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qualiﬁcation. In another study, CTX-II levels reached at 6 months
were associated with radiological progression at 24 months19,
deﬁned a priori as a JSN of 0.6 mm from baseline which corre-
sponds to three times the SD of the X-ray measurement method for
joint space19. Three clinical trials in OA18,19,88 have used baseline
levels, or early change of a biomarker (CTX-II, MMP-3), to predict
subsequent progression of radiological damage. These studies
demonstrate the advantages of selecting a high matrix turnover/
progressor patient population for trial inclusion.
Other studies evaluated biomarkers with patient centered (self-
reported) clinical endpoints. A study with 53 patients receiving oral
calcitonin daily for 84 days showed that CTX-II, C2C, and MMP-13
levels were decreased in the group of patients receiving 1 mg/day
of calcitonin. The efﬁcacy of the treatment was evaluated by
Lequesne’s index73. A small Japanese study with 28 patients with
knee OA evaluated the effects of repeated injections of hyaluronan
and showed a signiﬁcant reduction of C6S, C4S and KS relative to
baseline. However, a vehicle treated control group was not evalu-
ated and it would be important to rule out changes in biomarkers
due to SF aspiration alone. The effect of this treatment was evalu-
ated by change in knee pain assessed by a VAS95.
Level of qualiﬁcation of OA-related biomarkers
The following, Tables III and IV, summarizeOA-relatedbiomarkers
used to date in human clinical trials described in Table II and/or
commercially available. Speciﬁcally, Table III lists commercially
available biomarkers currently recommended as a panel for study in
past and future clinical trials (discussed in Conclusions and Recom-
mendations-Recommendations to advance the science of
biomarkers), and Table IV lists other OA-related biomarkers qualiﬁed
for various OA outcomes. The BIPEDS classiﬁcation assignments are
based on studies in which the biomarker showed a statistically
signiﬁcant difference for a clinical or structural outcome as summa-
rized primarily by van Spil62 but also by Cibere 200915; Conrozier
2008101; andKraus201050. The Surrogate classiﬁcation is restricted to
results based on current published human clinical trials only. These
designations could be further reﬁned bya consideration of preclinicalTable IV
Other OA-related biomarkers qualiﬁed for various OA outcomes
Biomarker Process (preliminary) Tissues of origin (see
discussion below Table)
BIPEDS
classiﬁcati
Serum KS Cartilage catabolism,
aggrecan
Cartilage Knee: BPE
Hip: none
Serum YKL-40 Catabolic; macrophages,
cartilage, synovium, cells
of epithelial origin
Macrophages, cartilage,
synovium, cells of
epithelial origin
Knee: BE
Hip: D
Urinary TIINE Cartilage catabolism
type II collagen
Cartilage Knee: BP
Hip: none
Serum OC Anabolic bone turnover Bone Knee: BPE
Hip: none
Urinary
Glc-Gal-PYD
Catabolic synovium Synovium Knee: BD
Hip: none
Urinary PYD Catabolic bone turnover Bone Knee: BED
Hip: none
Urinary DPD Catabolic bone turnover Bone Knee: BED
Hip: none
MMP-13 Protease Synovium, cartilage Knee: E
Hip: none
Table II abbreviations: uTIINE (mAbs 9A4/5109)¼ urinary type II collagen collagenase-gresults and unpublished results if a repository of this knowledge
existed as called for in the recommendations of this document.
Although type II collagen is an attractive candidate marker of
cartilage degradation, it can be difﬁcult to precisely identify the
principle tissue sources of a biomarker and the sourcewithin a tissue
such as articular cartilage which is composed of both calciﬁed
(adjacent to subchondral bone) and non-calciﬁed regions. A case in
point is represented by the biomarker CTX-II, the most widely tested
OA-related biomarker to date. The CTX-II assay exists in two forms:
a sandwich ELISA used for animal serum samples that likely recog-
nizes a dimeric form of the EKGPDP epitope; and a competitive ELISA
used for human and animal urine samples that likely recognizes
monomeric and dimeric forms of the EKGPDP collagen II telopep-
tide67. Unlike the collagen epitope urinary TIINE40, the exact nature of
the immunoreactive cleavageproducts inurinehasnot been reported
for CTX-II. EKGPDP is released fromdenatured human type II collagen
upon enzymatic digestion with matrilysin, and MMPs-3, -8,
and -13102, and in another study from cartilage sections by enzymatic
digestions with MMPs-1, -3, -7, -9, and -13 and cathepsin B103. CTX-II
immunoreactive epitope can also be released in vitro from non-
mineralized bovine articular cartilage treated with oncostatin M and
TNFalpha and its release can be blocked by estrogen104. In young
animals and skeletally immaturehumans, a signiﬁcant amountof this
epitope originates fromgrowth plate cartilage105e107. In adult human
osteoarthritic cartilage CTX-II immunostaining is in uncalciﬁed
ﬁbrillated cartilage as well as calciﬁed articular cartilage108.
Further complicating the interpretation of collagen type II
fragment origins, are the many sites where type II collagen is found
in skeletally mature adults, including: articular cartilage, ﬁbro-
cartilage (intervertebral disc, menisci), respiratory tract cartilage,
rib cartilage, insertion sites of tendons and ligaments into bone, and
to a small extent, in the ear and eye63. However, as pointed out by
Lohmander and Eyre, type II collagen makes up only w1% of all
collagen in the body but the normal turnover is low suggesting that
pathological turnover from a single joint might be expected to raise
the systemic level of fragments signiﬁcantly63.
Finally, CTX-II urine levels are very low in individuals with
pycnodysostosis compared with age-matched controls63.ons
Surrogacy based on human
clinical trials (preliminary)
ELISA assay type
D Demonstration: changed signiﬁcantly in
one pharmacologic trial meeting primary
clinical endpoints93
Competitive-inhibition
(not commercially available)
Demonstration: changed signiﬁcantly in
one pharmacologic trial meeting
primary clinical endpoints99
(Not commercially available)
Exploration: paradoxical response69 (Not commercially available)
D Demonstration: changed signiﬁcantly in
one pharmacologic trial meeting primary
clinical endpoints93
ELISA
Exploration: insigniﬁcant change in one
pharmacologic trial meeting primary
clinical endpoints70
HPLC
Demonstration: changed signiﬁcantly in
one pharmacologic trial meeting primary
clinical endpoints93
HPLC
Demonstration: changed signiﬁcantly
in one pharmacologic trial meeting
primary clinical endpoints93
HPLC
Demonstration: changed signiﬁcantly
in one pharmacologic trial meeting
primary clinical endpoints73
Sandwich for total
MMP-13 assay
enerated neoepitope; MMP¼matrix metalloproteinases:-13 (collagenase-3).
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by mutation of the gene encoding the enzyme cathepsin K,
a cysteine protease expressed by osteoclasts and a major protease
involved in bone resorption. In pycnodysostosis (OMIM #265800),
osteoclasts function normally in demineralizing bone, but do not
adequately degrade the organic matrix. This ﬁnding has suggested
that a major source of CTX-II is the breakdown and remodeling of
mineralized cartilage collagen by osteoclasts63,104. In fact, by
immunohistochemistry, the EKGPDP epitope is localized in calciﬁed
articular cartilage, at the interface between the calciﬁed cartilage
and bone, and to some extent at the surface of non-mineralized
cartilage lesions, as well as subchondral bone (in a rat model of
OA)104,108 Osteophyte formation and remodeling may thus also be
a signiﬁcant source of CTX-II since, like the growth plate, this also
involves endochondral ossiﬁcation and is a fundamental feature of
joint degeneration in OA. Urinary CTX-II has in fact been shown to
correlate with total body burden of osteophyte50.
In summary, and as illustrated here for the most reported OA
biomarker CTX-II, the complexities in structure, the paucity of
evidence on tissue origins, and the incompletely understood cata-
bolic, clearance, and regulatory pathways currently make it difﬁcult
to be certain of the principal sites of origin of OA-related
biomarkers. This serves to illustrate how critically important it is to
understand asmuch as we can about each of these biomarkers from
in vivo and in vitro analyses in order to be able to more precisely and
correctly interpret biomarker data in preclinical and clinical drug
development and assessment.
Summary related to use of biomarkers in clinical trials
There have been few published clinical trials reporting
biomarker results. The lack of medications with established chon-
droprotective activity has limited the availability of clinical trial
samples in which to test the utility of biomarkers.
In many cases, especially involving preclinical and clinical trials,
biomarker results may not be reported or are not reported in
a systematic and standardized manner. So it is difﬁcult to utilize
published data from trials to power future trials or to draw
conclusions by comparing across studies. Recommendations
regarding standardization and access to body ﬂuids can be found at
the end of this document.
Of those clinical trials reporting biomarker results, relatively few
biomarkers have been tested, often using different methodologies,
and very few trials and studies have tested multiple biomarkers in
the same samples. Only recently have a variety of biomarkers
started to be examined head to head in the same studies15.
Many promising OA-related biomarkers have never or rarely
been tested in clinical trial samples. Existing clinical trials have not
used standardized methods of sample collection and assay
methods differ among studies for many of the biomarkers tested.
Pathways for biomarker qualiﬁcation
The increased use of biomarkers is viewed as a critical compo-
nent in improving the traditional inefﬁciency of the OA drug
development process. Biomarkers can be used in a variety of ways
from drug target development in preclinical studies to surrogate
endpoints for regulatory approval. How biomarkers are used also
deﬁnes the level of qualiﬁcation required.
As described in the Introduction-Deﬁnition of biomarkers,
a biomarker may be deﬁned as “a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses to
a therapeutic intervention”2. The deﬁnition has two key compo-
nents; the measurement of the biomarker and its evaluation as an
indicator of some biological process(es). Consequently, anydiscussion of biomarker qualiﬁcation must include both charac-
terization of the source of the biomarker, the analytical capabilities
of the test used to quantify the biomarker, as well as the evaluation
(i.e., qualiﬁcation) of the association between the biomarker and
the pathobiological state and/or clinical outcome.
In general, companies are struggling with deﬁning and devel-
oping a process for what in vitro (soluble) biomarker data to include
in regulatory submissions39. Results intended to inﬂuence the
course of the clinical development process would be considered
part of the safety and efﬁcacy evaluation and would need to be part
of the regulatory submission39. Biomarker data that do not have
such a regulatory impact would not need to be part of the regula-
tory submission. This section describes some of the considerations
related to the biomarker qualiﬁcation process and pathway.
Assessment of analytical capabilities of a biomarker test
Analytical validation of a biomarker follows a different pathway
from that of validation of a drug. Validation of analytical methods
related to the drug itself is a well-deﬁned process. Regulatory
agencies require that critical parameters of tests performed to
assess the material conform with current Good Manufacturing
Practice109. The ICH has published detailed guidelines on the vali-
dation of analytical procedures included as part of a registration
application110. In the case of a drug or biologic development
process, analytical methods are considered acceptably validated if
the assays perform in a manner that demonstrates that the drug
substance or drug product has the appropriate identity, strength,
quality, and purity. There is an expectation by regulatory authori-
ties that the analytical capabilities of critical test methods will be
enhanced during the drug development process and that the
methods are fully validated at the time of the market application.
The contrasting process of biomarker validation was described
in the Qualiﬁcation of Known Biomarkers-Validation, and entails
assessment of the accuracy, precision, speciﬁcity [what process is it
measuring and in which tissue(s)], detection limit, quantiﬁcation
limit, linearity and range. In 1988, Congress passed the Clinical
Laboratory Improvement Amendments (CLIA) establishing quality
standards for all laboratory testing to ensure the accuracy, reli-
ability and timeliness of patient test results regardless of where the
test is performed.
Biomarker qualiﬁcation e association of a biomarker and a clinical
outcome
As mentioned earlier, qualiﬁcation and validation have different
meanings; biomarker qualiﬁcation consists of the process of asso-
ciating a biomarker with a clinical outcome or biological parameter.
Biomarker qualiﬁcation processes are in a state of evolution but
a recent document outlines the current pilot pathway and regula-
tory agencies involved44.
Levels of qualiﬁcation of biomarkers for drug development use
Biomarkers for drug development use can be divided into four
categories according to the degree or level that the biomarker can
be shown to be associated with the pathobiological state or clinical
outcome. An exploration level biomarker has some evidence of an
in vitro or preclinical association that may predict a clinical
outcome. This type of biomarker is often an outcome of scientiﬁc
research describing a pathway that may impact a clinical state. The
consistency of the data or correlation is low and would be used
primarily to support hypothesis generation.
A demonstration level biomarker has higher level of evidence of
a correlation between the biomarker and the clinical outcome. This
correlative data derive from limited clinical studies. This category is
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ance on the submission of pharmacogenomic data to FDA6 and the
process map proposal for validating genomic biomarkers by
Goodsaid and Frueh111. Often the association of the biomarker and
the clinical outcome is the result of a post-hoc analysis. While the
data showing the association between the biomarker and the
biological state may be promising, it is limited until further inde-
pendent veriﬁcation can be performed.
Characterization level biomarkers are reproducibly linked to
clinical outcomes in more than one prospective clinical study in
humans and have been independently veriﬁed. This category
corresponds to the “known valid” biomarkers in nomenclature
suggested in the FDA pharmacogenomic guidance and process map
proposal of Goodsaid and Frueh referenced earlier. These
biomarkers have been shown to be associated with clinical
outcomes as prospectively deﬁned endpoints and are appropriate
for making a range of decisions regarding the therapeutic being
studied. The biomarkers can be used to identify responders vs non-
responders, individuals that may be at risk for toxicity, or assist in
deﬁning the appropriate dose for an individual.
The ﬁnal category of biomarker qualiﬁcation is when the
biomarker can be used as a surrogate for a clinical outcome, and
thus can be used as the basis of a regulatory decision. Surrogate
level biomarkers should be considered a subset of characterization
level biomarkers. The use of a surrogate endpoint as the basis for
approval of a new drug requires prior agreement with the regula-
tory agency, and is also restricted to drugs that are intended to treat
serious and life-threatening illnesses112.
Biomarker qualiﬁcation can occur both during development of
a therapeutic113 and independent of a therapeutic. As described in
Biomarker Applications in Development of Therapeutics for Oste-
oarthritis, there are many uses for biomarkers that are independent
of a therapeutic; in addition they may assess characteristics related
to safety or toxicity, such as biomarkers that are correlated with
stress or damage to critical organs.
Biomarker qualiﬁcation independent of a therapeutic
Biomarkers that correlate with disease progression that are
developed independent of a therapeutic may be perfect tools for
identiﬁcation of promising new therapeutics. This type of
biomarker would be considered an exploration level biomarker.
Clinical studies would be required to develop the necessary data to
show if it can be categorized as a demonstration or characterization
level biomarker. Agencies involved include CLIA, the FDA and the
Center for Devices and Radiological Health (CDRH).
For the qualiﬁcation of biomarkers independent of a therapeutic,
a process map for the validation/qualiﬁcation of genomic biomarkers
of drug safety has been proposed111. The proposed process could
encompass biomarkers other than safety, such as biomarkers of
disease progression. As the authors state, the process can be consid-
ered intuitive as it follows well-established processes. Following the
identiﬁcation of a potential safety or disease progression biomarker
and the development of an appropriate analytical method, a qualiﬁ-
cation protocol can be proposed and discussed with the regulatory
agency. Once approved, the qualiﬁcation protocol could be executed
and the report submitted for review. If the data support the correla-
tion between the biomarker and the safety signal or disease
progression, then the biomarker could be considered qualiﬁed. The
level of qualiﬁcation could be dependent uponwhether the protocol
included independent or cross validation of the biomarker.
Biomarker qualiﬁcation in conjunction with a therapeutic
Biomarkers have been used in drug development for some time,
and this practice is expected to expand with the trend toward
personalized medicine. Because qualiﬁcation of a biomarker inconjunction with development of a therapeutic is usually done
within a single company, independent veriﬁcation is rarely feasible.
However, the process for qualiﬁcation would be comparable to the
process described earlier. Lesko and Atkinson describe in detail
a strategy for biomarker qualiﬁcation, and note that the criteria used
in the qualiﬁcation of any biomarker are dependent upon the
regulatory role a biomarker is expected to play114. In 2005, the FDA
published a concept paper on drug-diagnostic co-development115.
This draft document addresses issues related to the development of
a test that would bemandatory in the therapeutic use of a drug. Due
to the critical role the test would assume, the FDA recommends that
the co-development pathway should be determined early in devel-
opment and that the sponsor should consult with the appropriate
drug/biologic/device reviewing centers. The approval of a drug that
utilized the analysis of a biomarker as integral in the use of the drug
would require the parallel review and approval of the diagnostic.
Agencies involved including CLIA, the FDA, and CDRH.
Examples of biomarkers used for regulatory approval of
a therapeutic
There are no examples of biomarkers used for OA drug regis-
tration. However, examples are emerging in other ﬁelds of the
successful application of biomarkers in the development of drugs.
To date, the primary biomarkers qualiﬁed for use with a drug are
genomic. In fact, pharmacogenomic information is contained in
about 10% of labels for drugs approved by the FDA. The FDA has
published a list of valid genomic biomarkers in the context of these
FDA-approved drugs113. This list, containing approximately 30
drugs, provides the regulatory context in which the biomarker was
approved. Currently, only a few drugs recommend or require an
assessment of the biomarker in the context of prescribing the drug
or arriving at a therapeutic decision.
In summary, the pathway for qualiﬁcation of a biomarker is
deﬁned by how the biomarker will be used, the questions that are
addressed, and how closely the biomarker is associated with
a clinical outcome. The qualiﬁcation process can be viewed some-
what as a continuum, with a relatively low bar required of an
exploration level biomarker and the highest level required of
a surrogate level biomarker.
Conclusions and recommendations
General overview
This guidance document is being prepared at a time of rapid
biomarker evolution in this and other ﬁelds when studies are
revealing many promising and important contributions that could
be made by biomarkers to the development of new treatments for
OA. The advantages and potential opportunities offered by the use
of biomarkers can be traced from preclinical work involving labo-
ratory-based studies, through work with animal models of OA
extending into clinical trials and eventually into the treatment of
patients. The use and assessment of the value of these biomarkers is
seen as very much a work in progress, building on the lessons
learned to date and on the ongoing advances in the clinical and
imaging biomarker outcomes that form the basis for the qualifying
endpoints for non-imaging biomarkers. At the present time
biomarker usage will not provide primary outcomemeasures in OA
clinical trials; this in large part stems from the lack of an appro-
priate gold standard, which allows robust biomarker qualiﬁcation
with regard to symptomatic and structural outcomes. Because OA is
a whole organ disease with different tissues and biological
processes involved, a combination of a panel of biochemical
markers will probably be more powerful for the investigation of
V.B. Kraus et al. / Osteoarthritis and Cartilage 19 (2011) 515e542 533joint damage than assessment of a single biomarker15,25. The
potential for the effective clinical use of biomarkers may therefore
be more readily realized as biomarkers start to be included in OA
clinical trials, used in combination rather than individually, and
used in combination with imaging such as MRI35. It may, in the not
so distant future, become possible to use selected individual
markers or combinations thereof to inform decisions in clinical
trials and patient diagnosis, treatment and monitoring.
Summary of issues related to the application of biomarkers in the
development of drugs for OA
Preclinical studies
Biomarkers have already proven their relevance in preclinical
studies of arthritis onset, progression, treatment and outcomes.
This work includes studies of OA development in mice, rats, guinea
pigs, rabbits, horses and dogs, both induced and naturally occur-
ring. Studies with surgically induced joint instability can produce
signiﬁcant biomarker changes in peripheral blood and urine within
2e8 weeks of onset that parallel histologically demonstrated
cartilage degeneration. Therapeutic interventions during this
period are reﬂected by biomarker changes in these models.
Preclinical studies can be used to link changes in speciﬁc biomarker
parameters (i.e., magnitude of change with intervention and time
to measure change in biomarker from ﬁrst dose) to histological
beneﬁt and therefore inform regarding the use of these biomarkers
in clinical studies. Routine use of biomarkers for dose selection will
require establishing a link to structural and clinical outcomes.
Preclinical model studies of cartilage collagen biomarkers of
degradation and synthesis and COMP have proven to be of special
value. Such studies should provide valuable insights in human
clinical investigations. If biomarkers reﬂecting structural and/or
symptomatic changes can be identiﬁed in preclinical studies these
can then be considered for use in a clinical trial.
Clinical studies
 There are currently no recognized and approved “disease
modifying” therapeutic agents, therefore there is no valid
means bywhich to test the ability of biomarkers to changewith
therapy.
 Biomarkersmay serve as titration tools, facilitating dose setting
in early clinical studies.
 Although systemic biomarkers (serum and urine) potentially
reﬂect generalized OA (analogous to a global outcome
measure) and local (intra-articular) biomarkers reﬂect local OA,
in general, therapeutic studies are focused on one joint, often
knee or hip; data are not routinely collected on symptoms or
structure in other joints that may also be affected as part of
generalized OA and that may impact systemic biomarkers.
 Rescue medication and placebo effects confound trial results but
biomarkers provide objective outcomes with the potential to
overcome some of the inherent limitations of subjective
outcomes.
 Therapeutic trials include patients whose disease is likely to
respond to treatment based on symptomatic and imaging
criteria, but not biological criteria reﬂecting tissue metabolic
activities; whereas biomarkers and biomarker proﬁles have the
potential to identify molecular and/or metabolic subsets of
disease activity and progression that may reﬂect different
responses to a particular intervention.
 Biomarkers provide the only current potential means of iden-
tifying the early molecular stages of OA as deﬁned in Fig. 1.
These early changes, having been identiﬁed by a biomarker,
may be most susceptible to disease modiﬁcation, and alsomeasurable by that same biomarker, based on experiences
with biologic therapy in inﬂammatory arthritis17.
 A major reason for failure of OA clinical trials to date has been
lack of study power due to insufﬁcient numbers of progressors
with regard to imaging outcome.
 Biomarkers should offer both sensitive detection of patients
with active disease for inclusion in trials and monitoring of
effects on tissues.
 Biomarkers provide potential means of increasing trial power
with a speciﬁed sample size through enrichment of
a predominantly disease progressing patient population.
 Biomarkers provide potential to decrease the length of a trial or
facilitate early decision-making regarding the therapeutic
value of a treatment if early biomarker changes are predictive
of later clinical or structural outcomes; this has been exem-
pliﬁed to date by several biomarkers including CTX-II18,19,
MMP-388, and considering the combination of collagen
degradation and synthesis24,25.
 Although correlations of biomarkers to symptoms will be
informative, very short symptomatic trials may be too short to
reﬂect cartilage or bone biomarker level modiﬁcations.
 We lack information on the impact of therapy on biomarkers in
generalized OA.
 One shortcoming of most biomarker studies is the failure to
account for total body burden of disease.
 Proof of concept studies with serum COMP have shown that
systemic concentrations in the serum report on burden of
(systemic) disease while intra-articular concentrations report
on local disease features47.
 Little to date is known about markers speciﬁc for a particular
joint site.
 The use of systemic biomarkers to report on local disease at
a speciﬁc joint site tends to be confounded by high background
from turnover in other cartilage tissues including the spine48.
 There is a validated measure to evaluate spine OA structural
changes116 that could serve as an endpoint on which to qualify
a biomarker for spine OA as exempliﬁed by one past study48.
 There is no deﬁnitive “gold standard” for assessing structural
changes in all joint tissues with imaging techniques thus
hampering the ability to qualify a biomarker for structural
endpoints; sampling of ﬂuid from a given joint will circumvent
this problem in a trial.
 Statistically signiﬁcant biomarker differences may not correlate
with clinically meaningful differences in symptomatic or
imaging endpoints.
 The interpretation of the biomarker values in urine and blood
must take into account the possible confounders such as age,
gender, body mass index, ethnicity, diurnal changes, food
intake, physical activity and post-menopausal status.
 These confounders require that the biological ﬂuids be
collected at well deﬁned times, with standardized procedures,
accounting for all known confounders.
 Levels of biomarkers measured in blood and urine provide
information on systemic skeletal tissue turnover and are not
necessarily speciﬁc for the alterations occurring in a single
affected joint.
 The clearance of the biomarkermay also be affected to different
extents by physical activity, time of day, and liver and kidney
function. At the joint level, biochemical marker clearance may
also vary with synovial inﬂammation.
 The use of multiple biomarkers that represent various
components of the complex OA disease pathway, such as tissue
synthesis, destruction and inﬂammation, may yield interme-
diate endpoints that offer a more comprehensive assessment of
treatment effects such as impact on catabolism and anabolism.
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biomarker data, appropriate analytical validation of biomarker
assays is essential to ensure high-quality data to maximize the
value of such decisions39.
 Many promising OA-related biomarkers have never been tested
in appropriate clinical trial samples, often because of lack of
access to samples by those developing assays, so it is premature
to ﬁnalize the choice of the optimal biomarker(s) for OA trials.
 No single biomarker will be representative of all aspects of the
biological changes in the complex organ represented by the
joint.
 To encourage the application of biochemical and genomic
biomarkers in drug development, a consensus on how to
interpret results from these measurements is needed for
regulatory submissions.
Difﬁculties encountered
Historically, much work on biomarkers has suffered from
a number of limitations and obstacles. First among these include
difﬁculties encountered in translating new biomarker assays
developed in the laboratory into preclinical animal models and
human clinical trials. Often scientists working independently with
animal models and in clinics have had difﬁculties accessing
appropriate collaborative opportunities for biomarker application
and assessment. Researchers and companies developing biomarker
assays continue to have serious problems evaluating assays due to
inability to gain access to clinical samples, especially those from
clinical trials. Also many assays do not cross-react between human
and other species requiring the development of multiple assays.
Second, although early events of the OA-process should be optimal
for intervention, clinical studies focused on early disease have been
very limited (the Cibere et al. 2009 study being a notable
example15). Diagnosis of OA is typically made late in the disease
process and no DMOADs are currently available for treatment,
patients are often missed during the early phases of OA. A third
obstacle hampering the application of biomarkers has been the lack
of understanding of how the processes leading to tissue destruction
also lead to symptoms and other clinical parameters and whether
there are molecular indicators that correlate with these parame-
ters. Another unknown is whether or how the processes vary over
the progression of the disease. Soluble biomarkers are potentially
as complex and varied as the biology they model but have the
challenge of being qualiﬁed based on relatively generic symptom-
atic and structural outcomes. These obstacles form the basis of
a research agenda for the study of OA biomarkers informed by the
recommendations below. Fourth, investigators tend to study
a single biomarker or a limited set of biomarkers at the exclusion of
others. This trend is beginning to change with increased under-
standing of the need to evaluate many different biomarkers
together within a given study. Information can be learned from
these biomarkers both individually and in combination as well as in
combination with imaging markers.
Critical needs
 To develop better structural endpoints for biomarker
qualiﬁcation;
 To develop biomarkers for various stages of disease;
 To develop biomarkers reporting on speciﬁc joint sites and to
elucidate the speciﬁc joint site contributions to the systemic
concentrations of existing biomarkers;
 To determine the clearance of biomarkers from the joint, from
the lymphatics, and from the blood as well as the renal pro-
cessing and elimination via the urine and the effect on their
correlation with disease progression; To assess if there is a circadian rhythm in the level of
a biomarker in a particular matrix to better design the sample
collection schedule and the interpretation of the results;
 To assess if there are covariates that affect the concentration of
a biomarker in the selected matrix such as age, gender, BMI,
concomitant diseases/medications, or joint site involvement;
 To study a wide-variety of patient types with varied clinical
characteristics and joint-site involvement;
 To develop biomarkers ﬁt-to-purpose;
 To establish an ongoing critical assessment of the value of
existing biomarkers in clinical trials;
 To establish minimal clinically important differences in
biomarkers once the minimal clinical important differences are
deﬁned for the qualifying endpoints for biomarkers, namely in
symptomatic and structural endpoints;
 To be able to gain easier access to body ﬂuids from past, present
and future clinical trials to enable more comprehensive and
critical head to head evaluations of existing and new
biomarkers for use in clinical trials;
 To develop multiplex assays incorporating existing promising
biomarkers to provide efﬁcient, cost-effective assays informing
on multiple domains of joint biology and response to therapy
while minimizing demands for sample;
 To increase the available knowledge of biomarker responses in
clinical trials for biomarker qualiﬁcation and clearance by FDA
through public release by companies, of information related to
use of biomarkers in their preclinical and clinical trials.
Recommendations to advance the science of biomarkers
The availability of an expanding number of biomarkers provides
increasing opportunities to combine biomarkers to study disease-
subsets and to correlate these to clinical parameters and disease
outcome. We recommend measurement of a broad set of
biomarkers in available and future sample sets, and analysis of
biomarkers singly and in combination, to provide a more compre-
hensive assessment of ongoing disease and efﬁcacy of treatment.
We recommend that a panel of biomarkers be used to examine the
same samples and preferably in multiple past and future clinical
trials. The most appropriate biomarkers would be those related to
the proposed mechanism of drug action. The following commer-
cially available biomarkers, some often studied and others less
frequently, are nevertheless recommended for inclusion to provide
comparative data and biological insights fromwhich to continue to
assess the utility and relevance of an array of established OA-related
biomarkers: urinary CTX-II, serum COMP, serum hyaluronan, serum
and urine C1, 2C, serum and urine C2C, serum and urine Coll2-1 and
Coll2-1NO2, serum CPII, Serum PIIANP, urine/serum NTX-1, urine/
serum CTX-1, serum CS846, and serum MMP-3. This panel is
considered an initial starting point for a process in evolution. As
knowledge is gained and additional OA-qualiﬁed biomarkers
become either commercially or readily available to the OA
communityof investigators, it is anticipated that thiswill be revised.
 Recommendations should be developed for biomarker data
presentation in publications from research studies and clinical
trials. For clinical trials, this should include, at a minimum,
reporting of the mean and SDs (in all groups before and after
treatment) of biomarker concentrations and inter- and intra-
assay variation.
 Minimal meaningful differences for biomarkers need to be
deﬁned and established and this can be done even in the
absence of a treatment study in a longitudinal trial. A critical
component for the success of this aimwill be the establishment
of clinically meaningful endpoints related to imaging and
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endpoints for biomarker studies.
 For clinical trials, consideration should be given to listing inten-
ded biomarker analyses at ClinicalTrials.gov in addition to
primaryclinical endpoints; alternatively, a separatewebsite could
be considered to serve the purpose of tracking and reporting this
information, results (both positive and negative apropos of next
recommendation), and stimulating advances in the ﬁeld.
 Biomarker data, both positive and negative, ideally should be
released in a timely manner into the public domain, preferably
by peer-reviewed publication. This will ensure the optimal
development and use of important biomarker tools as exem-
pliﬁed in this guidance document. It will also serve to maintain
the momentum generated by a recent increase in collaborative
research on biomarkers of OA, ensuring that this continues as
a concerted effort to serve the broader stakeholder community
to solve common problems. This information could and should
be summarized and included in a public database that is
managed and regularly updated on a monthly basis.
 Resources should be made available to encourage, through
a carefully controlled peer review process, access to body ﬂuids
from cohorts such as those harvested from studies of OA onset,
progression andOAclinical trials.Many such cohorts are presently
available for study (see proceedings of OARSI Biomarker Work-
shop,Bethesda,MD,2009) (seehttp://www.oarsi.org/index2.cfm?
section¼Meetings_Events&content¼OABiomarker). In addition,
an effort also needs to be made to obtain cohorts depicting early
events, including sample sets for investigation of risk groups after
joint trauma, and past and future clinical trial sample sets.
 We note that in existing clinical trials, there has been no
standardized method of sample collection. We call for
a consensus regarding collection methods and recommend
practices in Appendix A.
 We recommend body ﬂuid collection and sample banking in
future human (in particular all future prospective OA clinical
trials) and animal studies to include serum and plasma, RNA
and DNA isolated fromwhole blood, urine, and where possible,
SF. SF is included since it represents the most proximal ﬂuid to
the joint and can provide the most direct insight into joint
metabolism in the case of biochemical and molecular
biomarkers. Peripheral white blood cells exhibit changes in
gene expression in OA that are detectable by microarray and
polymerase chain reaction (PCR) analyses117,118. The process of
cell isolation may be associated with artifactual gene expres-
sion changes so the collection of whole blood (via PaxGene or
Tempus tubes), in lieu of cell isolation, may be preferable for
studies of gene expression. Just as the FDA has encouraged
voluntary submission of pharmacogenomic data in an effort to
increase the knowledge base for therapeutic candidates
(see http://www.fda.gov/oc/initiatives/criticalpath/Lesko/Lesko.
html)39, and in view of encouraging successful biomarker
developments of this kind in other ﬁelds (described in Examples
of Biomarkers Used for Regulatory Approval of a Therapeutic),
we recommend collection of whole blood for future genomic
analyses of gene expression in OA clinical trials.
 Since patterns of fragments may vary in different body ﬂuids
due to processing in the kidney, we recommend that both urine
and serum samples be collected and analyzed when biomarker
assays are available for use with both these body ﬂuids.
 Protocols enrolling patients with knee or hip OA (the so-called
signal joints) have made measuring and interpreting treatment
effects easier, and thedevelopmentof speciﬁcOAmeasurements
has paralleled, and in some ways guided, this signal joint
approach. However, exclusive focus on the signal joint will miss
what is happening at other OA sites that could affect systemicbiomarker concentrations. For this reason it is recommended
that clinical trials for OA that include systemic (serum, urine)
biomarkers, collect information about other joints in addition to
the target joint, such as by using a patient global assessment, or
taking speciﬁc non-signal-joint measurements. Future devel-
opments may demonstrate that the status of particular joints
can be distinguished even in the setting of generalized OA.
 Immunoassays based on monoclonal antibodies are preferred
(or similar highly speciﬁc reactive agents such as those
produced by phage libraries). The ability to accurately and
quantitatively measure the concentration of epitopes in body
ﬂuids is a primary requisite for all assays. Competition immu-
noassays using a single antibody are often subject to higher
assay variability than sandwich assays in which intra- and
inter-assay variability can be minimized by use of, ideally, two
monoclonal antibodies with different epitope speciﬁcities.
Sandwich assays however may be problematic with small
fragments when these do not span two epitopes. The reliance
on polyclonal antisera makes it difﬁcult to ensure continuing
assay standardization when new antisera must be raised to
replace depleted supplies. The incorporation of an appropriate
standard is also an essential requirement for all immunoassays.
 In cases where multiple assays are available for the same
analyte, these assays should be compared against each other as
different information may be generated according to epitope
recognition.
 Although technically challenging, for all existing and future
assays, validation of assay speciﬁcity should include epitope
identiﬁcation of protein epitopes consisting of sequence veri-
ﬁcation of the epitope(s) being measured by their isolation and
characterization from the sample under investigation using the
antibodies that constitute the assay in combination with
methods such as mass spectrometry. An example is provided
by Nemirovskiy et al.40 who examined the peptides in urine
generated by collagenase cleavage of type II collagen and
bound by the uTIINE antibody.
 For an improved understanding of a biomarker, the principle
tissue source(s) of a given biomarker should be identiﬁed as
accurately as possible, so that the origin(s) of the epitope(s) is/
are clearly understood. These requirements are essential for
a clear understanding of what the assay results represent and
for the interpretation of data when biochemical and molecular
biomarkers are used in preclinical or clinical studies.
 Assays developed in independent laboratories should be made
available either commercially or through collaborative
agreements.
 For the most effective assessment of existing and new
biomarkers, strong collaborations involving both the academic
and commercial sectors are essential so that accessibility to
body ﬂuids and different biomarker assays in past, present and
future clinical trials is ensured. It is possible to envision a time
when an expert advisory group could manage this and that one
or more central reference laboratories perform assays in
a standardized manner in both biomarker assessment/valida-
tion and in preclinical and clinical trials.
 Data on epitope stability with storage, and freezing and
thawing, should be standardized and available in the public
domain.
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Appendix A. Sample acquisition and handling
Introduction to sample handing and considerations relevant
to all samples: the measurement of biomarkers in biological
samples has the potential to provide information on diagnosis,
evaluation of risk, assessment of prognosis, monitoring treatment,
prediction of response to treatment and as a surrogate response
marker119. Biomarkers can be evaluated in a wide array of ﬂuids or
tissues depending on the pathology to be monitored. In this
Appendix, we focus on the collection and storage of blood, urine,
and SF for the assessment of onset and disease activity in OA. For all
samples intended for biomarker analysis, the sample quality is
dependent on two major factors: the pre-analytical parameters
(methods used for sample collection, handling, processing) and the
storage conditions (duration of storage, storage temperature,
number of thaws)119. The time from body ﬂuid sampling to storage
should be reduced to a minimum to avoid degradation. There is
a consensus that a temperature below 70C is required for long-
term stability of protein epitopes, although good prospective data
on stability in frozen samples are missing for most assays or havenot been published. Likewise, it is ideal to perform biomarker
analyses as soon after sampling as possible. However, to avoid assay
batch effects, it is best, when possible, to run all samples from
a particular study at one time and to examine samples from the
same patient on the same plate. For a clinical trial, the storage time
prior to analyses may be kept to a minimum but this is less readily
implemented for routine use. Epitope stability for each assay
should be clearly established with respect to duration of storage
and effects of freezing and thawing to ensure validity of the
measurements. Samples for immunoassays should be aliquoted on
isolation into volumes suitable for at least a single immunoassay in
triplicate. A volume of 175 ml is generally recommended to be
sufﬁcient to accommodate most assays run in triplicate. With
technical improvements in assay design in future, much smaller
volumes should be able to be accommodated. The time of day of
sample collection should be standardized and noted (recommend
AM or PM at least 2 h after rising and/or any meals for blood and
second morning void for urines). The body ﬂuid collection for
human and animal studies should include serum, plasma (to avoid
the proteolysis that may be activated in blood coagulation), urine,
and where possible, SF samples. Although collection of SF presents
some unique challenges in both patients and animal studies, this
sample represents the most proximal ﬂuid to the joint and can
provide the most direct insight into joint metabolism in the case of
biochemical and molecular biomarkers. Whole blood should be
collected in appropriate tubes to permit biomarker studies of gene
expression and genetic polymorphisms. Robust standardized
protocols for sample collection, handling, and storage should be
developed and adhered to for high quality biomarker analyses.
Blood collection, handling, and recommendations: blood
should be collected and stored separately as serum, plasma, and
whole blood. Some assays work better in serum and some only in
plasma so the acquisition of both provides for maximal possible
assays, as exempliﬁed by assays for theMMPs120. The speciﬁc needs
of the assay should be carefully checked in advance. For instance,
consideration must be given to the potential for altered protein
conformations and immunoreactivity in an assay upon chelation of
divalent cations. Patients can be fasted overnight prior to blood
collection but this is often found not necessary. Plasma should be
collected into a commercial collection tube with anticoagulant
added [commonly ethylenediaminetetraacetic acid (EDTA), citrate,
or heparin] followed by centrifugation. The effect of different anti-
coagulants on the analyte should be examined119 as the require-
ments differ for different assays. For instance, EDTA and citrate
plasma are unsuitable for MMP activity assays as these anticoagu-
lants chelate calcium required for MMP activity. For serum, blood
should be collected in a red top tube without additives. Serum
separator (SST) tubes are particularly easy to use and minimize
contaminationof serumbyclot; they have been successfully used for
several years by some researchers (VBK). Upon blood collection, the
plasma or serum tube is immediately gently inverted 3e5 times, and
allowed to clot at room temperature for at least 30 min (maximum
60 min to avoid subsequent ﬁbrinolysis), followed by centrifugation
at approximately 1300g (w3500 rpm) for 10 min to separate the
plasma from the buffy coat and red blood cells (anticoagulant tube),
or to separate the serum from the clot (tube without additives). The
supernatant from both plasma and serumcollection tubes should be
aliquoted into small fresh cryotubes (recommended 100 or 175 ml
aliquots according to the assay noting the volume to monitor for
potential subsequent dessication of sample) and frozen
below 70C. Depending on the intended use of the sample, mixed
protease inhibitors canbe added tobloodsample collections to avoid
degradation of speciﬁc analytes of interest. The material composi-
tion of the tube can affect measurement of analytes so it is recom-
mended to use identical tubes for all samples within a study.
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the PaxGene blood collection tube (Becton Dickinson) can be used
to obtain RNA and DNA from whole blood. RNA extraction can be
performed using Qiagen’s PaxGene 96 blood RNA kit. RNA ampli-
ﬁcation can be achieved using Ambion Illumina AMIL1791 Total
Prep RNA ampliﬁcation kit. DNA isolation can also be achieved from
these tubes as described121. An alternative but similar system is
provided by Tempus tubes (Applied Biosystems). A successful
example of blood-derived gene expression analysis in OA is
provided by Marshall 2005117 although in vitro manipulation of
cells is ideally to be avoided in favor of direct RNA isolation with
PAXGene or Tempus tubes.
Urine collection, handing and recommendations: a second
morning void urine specimen is recommended as the standard for
biomarker assays. Prior to aliquoting (1 ml aliquots recommended
for urine), samples should be centrifuged at approximately 1300g
for 10 min to remove any debris. As with blood samples, collection
of urine samples should use a standardized tube and aliquoted
supernatants should be stored, as for serum and plasma, in cry-
otubes below 70C until measurements are made. Biomarker
levels in urine are subject to dilutional variances due to varying
hydration level and urine ﬂow rate (volume produced/time) or total
volume. This requires adjustment for differences in ﬂow rate or
volume to allow comparison of samples collected from different
patients or from the same patient over time and is most commonly
achieved through normalization of urine biomarker values with
urinary creatinine, although urinary creatinine is inﬂuenced by age,
diet, exercise, muscle mass, medications, tubular secretion and
glomerular ﬁltration rate122.
SF collection, handling, and recommendations: SFs can be
aspirated directly in many cases, but if necessary, a small volume
(10 ml) of sterile saline can be injected into the knee followed by
aspiration of all obtainable ﬂuid47. Using this technique, only one
needle insertion is required for human studies. For animal studies
(usually performed under anesthesia except in rabbits), it is rec-
ommended that the needle bewithdrawn after saline injection, and
the knee ﬂexed and extended 10 times to ensure mixing; this
procedure can also potentially increase the yield of ﬂuid aspirated.
To obtain a total white blood cell count in the sample, 25 ml of SF
can be mixed with 25 ml of trypan blue and the cell count per-
formed with a hemocytometer. SF samples should be cleared by
centrifugation (approximately 1300g for 10 min) and the remaining
supernatant ﬂuid aliquoted (100 ml) and stored in cryotubes
at 80C for future assays. In cases where 10 ml lavage samples
were obtained, a nearly simultaneous serum sample should also be
obtained in order to determine the dilutional factor of the SF for
subsequent correction of biomarker concentrations for this dilu-
tional effect. The dilution factor can be determined as described by
Kraus et al.123 based onmeasuring urea concentrations in the SF and
serum. SF up to 2.5-fold diluted shows a similar mass spectroscopic
proﬁle as SF aspirated directly (V. Kraus unpublished data); beyond
this level of dilution there may be some specimen heterogeneity
introduced by lack of mixing.
In the case of small animals, such as mice, a published method-
ology is available for obtaining SF at the time of sacriﬁce124. This
utilizes an alginate product with high absorbancy that wicks the
ﬂuid from the joint. Themethod has to be tested for each biomarker
or analyte of interest to insure that the alginate or the buffer
components do not interfere with the assay but to date has been
shown to be compatible with SF COMP124 and IL-1 (VBK unpub-
lished). For rabbits, Poole et al. 1978125 have used a 1e2 ml saline
injection, containing the tissue culture dye neutral red, into the stiﬂe
(knee) joint. Dilution and hence original SF volume is determined by
spectrophotometric examination of dye concentration. Intra-artic-
ular injectionvolumes, determinedby the relative size of the animal,should be used for other species in relation to the rabbit. However,
this weakly cationic dye penetrates cell membranes by non-ionic
diffusion and binds intracellularly to sites of the lysosomal
matrix126; thesedyepropertiesmayconfound thedeterminations of
dilution factor by this method. In the past, Evans blue and indoc-
yanine green dyes were shown to be inappropriate for monitoring
dilutional effects of lavage because of their absorption and metab-
olism by intra-articular cells and precipitation upon exposure to
SF123. Another useful approach for small animals (rats, guinea pigs,
rabbits) at sacriﬁce is to blot the surfaces of the opened joint with
a pre-weighed ﬁlter paper and then immediately record the weight
with the SF blotted. This will provide a measure of the amount of
non-diluted ﬂuid. Biomarkers can be readily eluted from the paper
as described and validated previously124. Thismethodworkswell in
the guinea pig127,128. Biomarker ratios can also be calculated in joint
ﬂuids where dilutions cannot be determined. These are indepen-
dent of dilution and provide useful data (RP unpublished).
Appendix B. Deﬁnitions of biomarker terms
Exploratory biomarker: research and development tools
accompanied by in vitro and/or preclinical evidence, but there is no
consistent information linking the biomarker to clinical outcomes
in humans. Used for hypothesis generation. First level of surrogacy
based on Wagner et al.1
Demonstration biomarker: associated with adequate preclin-
ical sensitivity and speciﬁcity and linked with clinical outcomes,
but has not been reproducibly demonstrated in clinical studies. This
category corresponds to “probable valid biomarkers” in nomen-
clature suggested in draft guidance from FDA. Used in decision-
making; provides supporting evidence for primary clinical
evidence. Second level of surrogacy based on Wagner et al.1
Characterization biomarker: associated with adequate
preclinical sensitivity and speciﬁcity and reproducibly linked to
clinical outcomes in more than one prospective clinical study in
humans. This category corresponds to “known valid biomarkers” in
nomenclature suggested in guidance by FDA. Used in decision-
making, and dose ﬁnding, for secondary/tertiary claims. Third level
of surrogacy based on Wagner et al.1
Surrogate biomarker: a holistic evaluation of the available data
demonstrates that the biomarker can substitute for a clinical
endpoint. The designation of “surrogate end point” requires
agreement with regulatory authorities. Used for drug registration.
Fourth level of surrogacy based on Wagner et al.1
Valid biomarker: has been deﬁned in the “Guidance for
Industry: Pharmacogenomic Data Submissions”. Therein, a valid
biomarker is described as a “biomarker that is measured in an
analytical test system with well established performance charac-
teristics and for which there is an established scientiﬁc framework
or body of evidence that elucidates the physiologic, toxicologic,
pharmacologic, or clinical signiﬁcance of the test results.” The
classiﬁcation of biomarkers is context speciﬁc. (http://www.fda.
gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/
ucm083378.htm).
Analytic validity: test’s ability to accurately and reliably detect
the epitope of interest.
Format: commercial availability, single or multiplex, type of
assay (ELISA or mass spectroscopy, etc).
Qualiﬁcation endpoints: symptoms; structure: radiographic
OA, pre-radiographic OA; molecular OA.
The following are summarized from the ICH of Pharmaceuticals
for Human Use110.
Accuracy: expresses the closeness of agreement between the
value that is accepted either as a conventional true value or an
accepted reference value and the value found.
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that can be detected but not necessarily quantiﬁed as an exact
value.
Linearity: is the ability of an analytical procedure (within
a given range) to obtain test results which are directly proportional
to the concentration (amount) of analyte in the sample.
Precision: expresses the closeness of agreement (degree of
scatter) between a series of measurements obtained from multiple
sampling of the same homogeneous sample under the prescribed
conditions. Precision may be considered at three levels: repeat-
ability, intermediate precision and reproducibility.
Repeatability: expresses the precision under the same oper-
ating conditions over a short interval of time and is also termed
intra-assay precision.
Intermediate precision: expresses within-laboratories varia-
tions: different days, different analysts, different equipment, etc.
Reproducibility: expresses the precision between laboratories
(collaborative studies, usually applied to standardization of
methodology).
Quantitation limit: is the lowest amount of analyte in a sample
that can be quantitatively determined with suitable precision and
accuracy.
Range: the interval between the upper and lower concentration
(amounts) of analyte in the sample (including these concentra-
tions) for which it has been demonstrated that the analytical
procedure has a suitable level of precision, accuracy and linearity.
Robustness: a measure of its capacity to remain unaffected by
small, but deliberate variations in method parameters and provides
an indication of its reliability during normal usage.
Speciﬁcity: the ability to assess unequivocally the analyte in the
presence of components that may be expected to be present.
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